UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
TPG
Inc.
(Name of Issuer)
Class
A Common Stock, $0.001 par value per share
(Title of Class of Securities)
872657101
(CUSIP Number)
Bradford Berenson
TPG Inc.
301 Commerce Street, Suite 3300
Fort Worth, TX 76102
(817)
871-4000
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
February
26, 2024
(Date of Event which Requires Filing of
this Statement)
If the filing person has previously filed a
statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. ☐
Note: Schedules filed in paper format
shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7(b) for other parties to whom
copies are to be sent.
(Continued on following pages)
(Page 1 of 10 Pages)
____________
*The remainder of this cover page shall be
filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934
(“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
CUSIP No. 872657101 |
SCHEDULE 13D |
Page 2 of 10 |
1 |
NAMES OF REPORTING PERSONS
TPG GP A, LLC |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) ☐
(b) ☐ |
3 |
SEC USE ONLY |
4 |
SOURCE OF FUNDS (see instructions)
OO (See Item 3) |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ☐ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
NUMBER OF SHARES |
7 |
SOLE VOTING POWER
- 0 - |
BENEFICIALLY OWNED BY |
8 |
SHARED VOTING POWER
264,003,487 (See Items 3, 4 and 5) |
EACH REPORTING PERSON |
9 |
SOLE DISPOSITIVE POWER
- 0 - |
WITH: |
10 |
SHARED DISPOSITIVE POWER
264,003,487 (See Items 3, 4 and 5) |
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
264,003,487 (See Items 3, 4 and 5) |
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) ☐ |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
74.1% (See Item 5)* |
14 |
TYPE OF REPORTING PERSON (see instructions)
OO |
|
|
|
|
|
* |
The calculation assumes that there is a total of 356,420,023 shares of Class A Common Stock (as defined below) outstanding, which is the sum of (i) the 74,762,397 shares of Class A Common Stock outstanding as of February 20, 2024, as reported in the Annual Report on Form 10-K filed by the Issuer (as defined below) with the Securities and Exchange Commission (the “Commission”) on February 23, 2024, (ii) the 17,704,987 shares of Class A Common Stock issued in connection with the Q1 2024 Exchange (as defined below), and (iii) the 263,952,639 shares of Class A Common Stock issuable upon exchange of 263,952,639 Common Units (as defined below) and the cancellation of a corresponding number of shares of Class B Common Stock (as defined below). |
CUSIP No. 872657101 |
SCHEDULE 13D |
Page 3 of 10 |
1 |
NAMES OF REPORTING PERSONS
David Bonderman |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) ☐
(b) ☐ |
3 |
SEC USE ONLY |
4 |
SOURCE OF FUNDS (see instructions)
OO (See Item 3) |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ☐ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
United States |
NUMBER OF SHARES |
7 |
SOLE VOTING POWER
1,571,865 |
BENEFICIALLY OWNED BY |
8 |
SHARED VOTING POWER
264,020,436 (See Items 3, 4 and 5) |
EACH REPORTING PERSON |
9 |
SOLE DISPOSITIVE POWER
1,571,865 |
WITH: |
10 |
SHARED DISPOSITIVE POWER
264,020,436 (See Items 3, 4 and 5) |
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
265,592,301 (See Items 3, 4 and 5) |
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) ☐ |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
74.5% (See Item 5)* |
14 |
TYPE OF REPORTING PERSON (see instructions)
IN |
|
|
|
|
|
* |
The calculation assumes that there is a total of 356,420,023 shares of Class A Common Stock outstanding, which is the sum of (i) the 74,762,397 shares of Class A Common Stock outstanding as of February 20, 2024, as reported in the Annual Report on Form 10-K filed by the Issuer with the Commission on February 23, 2024, (ii) the 17,704,987 shares of Class A Common Stock issued in connection with the Q1 2024 Exchange, and (iii) the 263,952,639 shares of Class A Common Stock issuable upon exchange of 263,952,639 Common Units and the cancellation of a corresponding number of shares of Class B Common Stock. |
CUSIP No. 872657101 |
SCHEDULE 13D |
Page 4 of 10 |
1 |
NAMES OF REPORTING PERSONS
James G. Coulter |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) ☐
(b) ☐ |
3 |
SEC USE ONLY |
4 |
SOURCE OF FUNDS (see instructions)
OO (See Item 3) |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ☐ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
United States |
NUMBER OF SHARES |
7 |
SOLE VOTING POWER
3,983,864 |
BENEFICIALLY OWNED BY |
8 |
SHARED VOTING POWER
264,020,436 (See Items 3, 4 and 5) |
EACH REPORTING PERSON |
9 |
SOLE DISPOSITIVE POWER
3,983,864 |
WITH: |
10 |
SHARED DISPOSITIVE POWER
264,020,436 (See Items 3, 4 and 5) |
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
268,004,300 (See Items 3, 4 and 5) |
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) ☐ |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
75.2% (See Item 5)* |
14 |
TYPE OF REPORTING PERSON (see instructions)
IN |
|
|
|
|
|
* |
The calculation assumes that there is a total of 356,420,023 shares of Class A Common Stock outstanding, which is the sum of (i) the 74,762,397 shares of Class A Common Stock outstanding as of February 20, 2024, as reported in the Annual Report on Form 10-K filed by the Issuer with the Commission on February 23, 2024, (ii) the 17,704,987 shares of Class A Common Stock issued in connection with the Q1 2024 Exchange, and (iii) the 263,952,639 shares of Class A Common Stock issuable upon exchange of 263,952,639 Common Units and the cancellation of a corresponding number of shares of Class B Common Stock. |
CUSIP No. 872657101 |
SCHEDULE 13D |
Page 5 of 10 |
1 |
NAMES OF REPORTING PERSONS
Jon Winkelried |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) ☐
(b) ☐ |
3 |
SEC USE ONLY |
4 |
SOURCE OF FUNDS (see instructions)
OO (See Item 3) |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ☐ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
United States |
NUMBER OF SHARES |
7 |
SOLE VOTING POWER
1,392,098 |
BENEFICIALLY OWNED BY |
8 |
SHARED VOTING POWER
264,003,487 (See Items 3, 4 and 5) |
EACH REPORTING PERSON |
9 |
SOLE DISPOSITIVE POWER
1,392,098 |
WITH: |
10 |
SHARED DISPOSITIVE POWER
264,003,487 (See Items 3, 4 and 5) |
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
265,395,585 (See Items 3, 4 and 5) |
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) ☐ |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
74.5% (See Item 5)* |
14 |
TYPE OF REPORTING PERSON (see instructions)
IN |
|
|
|
|
|
* |
The calculation assumes that there is a total of 356,420,023 shares of Class A Common Stock outstanding, which is the sum of (i) the 74,762,397 shares of Class A Common Stock outstanding as of February 20, 2024, as reported in the Annual Report on Form 10-K filed by the Issuer with the Commission on February 23, 2024, (ii) the 17,704,987 shares of Class A Common Stock issued in connection with the Q1 2024 Exchange, and (iii) the 263,952,639 shares of Class A Common Stock issuable upon exchange of 263,952,639 Common Units and the cancellation of a corresponding number of shares of Class B Common Stock. |
CUSIP No. 872657101 |
SCHEDULE 13D |
Page 6 of 10 |
This Amendment No. 2 (this
“Amendment”) amends and supplements the Schedule 13D filed by the Reporting Persons on November 2, 2023, as amended
and supplemented by Amendment No. 1 filed on December 4, 2023 (as so amended, the “Original Schedule 13D”
and, as amended and supplemented by this Amendment, the “Schedule 13D”), with respect to the shares of Class A Common
Stock. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to them in the Original
Schedule 13D.
Item 2. Identity and Background.
This Amendment amends and restates the second
paragraph of Item 2 of the Original Schedule 13D in its entirety as set forth below:
“TPG GP A, which directly holds 16,949
shares of Class A Common Stock, is the managing member of each of (i) TPG Group Holdings (SBS) Advisors, LLC, a Delaware limited liability
company, and (ii) Alabama Investments (Parallel) GP, LLC, a Delaware limited liability company. TPG Group Holdings (SBS) Advisors, LLC
is the general partner of TPG Group Holdings (SBS), L.P., a Delaware limited partnership, which directly holds (i) 33,899 shares
of Class A Common Stock and (ii) 210,947,654 shares of Class B common stock, $0.001 par value per share (“Class B Common Stock”),
of the Issuer.”
This Amendment amends and restates the fifth
paragraph of Item 2 of the Original Schedule 13D in its entirety as set forth below:
“Excluding the securities
beneficially owned by TPG GP A, TPG Group Holdings (SBS), L.P., New TPG GP Advisors, Inc. and the API Entities, Mr. Bonderman beneficially
owns directly or indirectly 1,571,865 shares of Class A Common Stock, Mr. Coulter beneficially owns directly or indirectly 3,983,864 shares
of Class A Common Stock and Mr. Winkelried beneficially owns directly or indirectly 1,392,098 shares of Class A Common Stock.”
Item 4. Purpose of Transaction.
This Amendment amends and supplements Item 4
of the Original Schedule 13D by deleting the third to last paragraph and inserting the following before the final paragraph:
“Q1 2024 Exchange
Pursuant to the Exchange Agreement, on February 26,
2024, 17,704,987 Common Units held by TPG Group Holdings (SBS), L.P. were ultimately distributed to certain partners of TPG Partner Holdings,
L.P. in connection with the exchange by such partners of those Common Units for an equal number of shares of Class A Common Stock and
the cancellation of an equal number of shares of Class B Common Stock (the “Q1 2024 Exchange”). In connection with
the Q1 2024 Exchange, entities controlled by Messrs. Bonderman, Coulter and Winkelried exchanged an aggregate of 1,500,000, 1,250,000
and 1,000,000 Common Units, respectively, for an equal number of shares of Class A Common Stock.
Q1 2024 Registered Offering
On February 26, 2024, TPG GP A, TPG Group
Holdings (SBS), L.P., New TPG GP Advisors, Inc., entities controlled by Messrs. Bonderman, Coulter and Winkelried and other selling stockholders
entered into an Underwriting Agreement (the “Q1 2024 Underwriting Agreement”) with J.P. Morgan Securities LLC and Morgan
Stanley & Co. LLC (the “Underwriters”), pursuant to which the selling stockholders agreed to sell an aggregate
of 15,526,915 shares of Class A Common Stock (the “Q1 2024 Registered Offering”). In the Q1 2024 Registered Offering,
TPG GP A agreed to sell 16,949 shares of Class A Common Stock, TPG Group Holdings (SBS), L.P. agreed to sell 33,899 shares of Class A
Common Stock, New TPG GP Advisors, Inc. agreed to sell 16,949 shares of Class A Common Stock, entities controlled by Mr. Bonderman agreed
to sell an aggregate of 1,533,898 shares of Class A Common Stock, entities controlled by Mr. Coulter agreed to sell an aggregate of 1,283,898
shares of Class A Common Stock and an entity controlled by Mr. Winkelried agreed to sell 1,000,000 shares of Class A Common Stock. The
Q1 2024 Registered Offering is expected to close on February 29, 2024.
CUSIP No. 872657101 |
SCHEDULE 13D |
Page 7 of 10 |
Q1 2024 Lock-Up Agreement
In connection with the Q1 2024 Registered Offering,
TPG GP A, TPG Group Holdings (SBS), L.P., New TPG GP Advisors, Inc., entities controlled by Messrs. Bonderman, Coulter and Winkelried
and the other partners of TPG Partner Holdings, L.P. agreed with the Underwriters, pursuant to a lock-up agreement (each, a “Q1
2024 Lock-Up Agreement”), that they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly
or indirectly, any shares of Class A Common Stock or any other securities so owned convertible or exercisable or exchangeable for shares
of Class A Common Stock (other than as contemplated by the Q1 2024 Underwriting Agreement or pursuant to certain other exceptions), without
the prior written consent of J.P. Morgan Securities LLC, for a period of 90 days after the date of the Q1 2024 Underwriting Agreement.
References to and the descriptions of the Transaction
Agreement, TPG GP A LLCA, Investor Rights Agreement, Exchange Agreement, TPG Operating Group Operating Agreement, Tax Receivable Agreement,
Q1 2024 Underwriting Agreement and Q1 2024 Lock-Up Agreement set forth above are not intended to be complete and are qualified, respectively,
in their entirety by reference to the full text of the Transaction Agreement, TPG GP A LLCA, Investor Rights Agreement, Exchange Agreement,
TPG Operating Group Operating Agreement, Tax Receivable Agreement, Q1 2024 Underwriting Agreement and Q1 2024 Lock-Up Agreement, which
are filed as exhibits hereto and are incorporated by reference herein.”
Item 5. Interest in Securities of the Issuer.
This Amendment amends and restates the second
paragraph of Item 5 of the Original Schedule 13D in its entirety as set forth below:
“(a)-(b) The following sentence
is based on a total of 356,420,023 shares of Class A Common Stock outstanding, which is the sum of (i) the 74,762,397 shares
of Class A Common Stock outstanding as of February 20, 2024, as reported in the Annual Report on Form 10-K filed by the Issuer with
the Commission on February 23, 2024, (ii) the 17,704,987 shares of Class A Common Stock issued in connection with the Q1 2024
Exchange, and (iii) the 263,952,639 shares of Class A Common Stock issuable upon exchange of 263,952,639 Common Units and the cancellation
of a corresponding number of shares of Class B Common Stock. Pursuant to Rule 13d-3 under the Act, TPG GP A may be deemed to beneficially
own 264,003,487 shares of Class A Common Stock, which constitutes approximately 74.1% of the outstanding shares of Class A Common Stock;
Mr. Bonderman may be deemed to beneficially own 265,592,301 shares of Class A Common Stock, which constitutes approximately 74.5% of the
outstanding shares of Class A Common Stock, and has pledged to a financial institution 24.99% of the “TPG Partner Units” he
holds in his capacity as a TPG partner, which units are exchangeable under certain circumstances for Common Units and shares of Class
B Common Stock held by TPG Group Holdings (SBS), L.P.; Mr. Coulter may be deemed to beneficially own 268,004,300 shares of Class A Common
Stock, which constitutes approximately 75.2% of the outstanding shares of Class A Common Stock; and Mr. Winkelried may be deemed to beneficially
own 265,395,585 shares of Class A Common Stock, which constitutes approximately 74.5% of the outstanding shares of Class A Common Stock.”
Item 7. Material to be Filed as Exhibits.
This Amendment amends and supplements Item
7 of the Original Schedule 13D by adding the following:
| “11. | Underwriting Agreement, dated February 26, 2024 by and among TPG Inc., the underwriters listed in Schedule 1 thereto and the
stockholders named in Schedule 2 thereto. |
| 12. | Form of Lock-Up Letter, by and among each of the selling stockholders listed in Schedule 2 to the Underwriting Agreement and the underwriters
listed in Schedule 1 thereto (incorporated by reference to Exhibit A to Exhibit 11 to this Schedule 13D).” |
CUSIP No. 872657101 |
SCHEDULE 13D |
Page 8 of 10 |
SIGNATURE
After reasonable inquiry and to the best of
my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 28, 2024
|
TPG GP A, LLC
|
|
By: |
/s/ Bradford Berenson |
|
Name: |
Bradford Berenson |
|
Title: |
General Counsel |
|
|
|
|
|
David Bonderman
|
|
|
|
By: |
/s/ Gerald Neugebauer on behalf of David Bonderman |
|
Name: |
Gerald Neugebauer on behalf of David Bonderman (1) |
|
|
|
|
James G. Coulter
|
|
|
|
By: |
/s/ Gerald Neugebauer on behalf of James G. Coulter |
|
Name: |
Gerald Neugebauer on behalf of James G. Coulter (2) |
|
Jon Winkelried
|
|
By: |
/s/ Gerald Neugebauer on behalf of Jon Winkelried |
|
Name: |
Gerald Neugebauer on behalf of Jon Winkelried (3) |
(1) Gerald Neugebauer is signing on behalf of Mr. Bonderman pursuant
to an authorization and designation letter dated January 10, 2024, which was previously filed with the Commission as an exhibit to
a Form 4 filed by Mr. Bonderman on February 7, 2024 (SEC File No. 001-41617).
(2) Gerald Neugebauer is signing on behalf of Mr. Coulter pursuant
to an authorization and designation letter dated January 10, 2024, which was previously filed with the Commission as an exhibit to
a Form 4 filed by Mr. Coulter on February 7, 2024 (SEC File No. 001-41617).
(3) Gerald Neugebauer is signing on behalf of Mr. Winkelried pursuant
to an authorization and designation letter dated January 10, 2024, which was previously filed with the Commission as an exhibit to
a Form 4 filed by Mr. Winkelried on February 7, 2024 (SEC File No. 001-41617).
CUSIP No. 872657101 |
SCHEDULE
13D |
Page 9 of 10 |
Exhibit
Index
| 1. | Agreement of Joint Filing by TPG Group Holdings (SBS) Advisors, Inc., TPG GP A, LLC, TPG Advisors VII,
Inc., TPG Advisors VI, Inc., TPG Advisors VI-AIV, Inc., TPG Asia Advisors VI, Inc., David Bonderman, James G. Coulter, Jon Winkelried
and Karl Peterson dated as of January 18, 2022 (incorporated herein by reference to Exhibit 1 to Amendment No. 4 to Schedule 13D filed
by TPG GP A, LLC, David Bonderman, James G. Coulter and Jon Winkelried on January 18, 2022 with respect to the shares of common stock
of Allogene Therapeutics, Inc.). |
| 2. | Transaction Agreement, dated May 14, 2023, among TPG Inc., TPG Operating Group II, L.P., TPG GP A, LLC,
Angelo, Gordon & Co., L.P., AG Funds, L.P., AG Partner Investments, L.P., Alabama Investments (Parallel) Founder A L.P., Alabama Investments
(Parallel) Founder G L.P., Alabama Investments (Parallel), LP, AG GP, LLC and Michael Gordon 2011 Revocable Trust (incorporated by reference
to Exhibit 2.1 to the Issuer’s Current Report on Form 8-K filed with the Commission on May 15, 2023). |
| 3. | Amendment No. 1 to Transaction Agreement, dated October 3, 2023, among TPG Inc., TPG Operating
Group II, L.P., TPG GP A, LLC, Angelo, Gordon & Co., L.P., AG Funds, L.P., AG Partner Investments, L.P., Alabama Investments
(Parallel) Founder A L.P., Alabama Investments (Parallel) Founder G L.P., Alabama Investments (Parallel), LP, AG GP, LLC and Michael Gordon
2011 Revocable Trust (incorporated by reference to Exhibit 2.2 to the Issuer’s Current Report on Form 8-K filed with the Commission
on November 2, 2023). |
| 4. | Amendment No. 2 to Transaction Agreement, dated October 31, 2023, among TPG Inc., TPG Operating
Group II, L.P., TPG GP A, LLC, Angelo, Gordon & Co., L.P., AG Funds, L.P., AG Partner Investments, L.P., Alabama Investments
(Parallel) Founder A L.P., Alabama Investments (Parallel) Founder G L.P., Alabama Investments (Parallel), LP, AG GP, LLC and Michael Gordon
2011 Revocable Trust (incorporated by reference to Exhibit 2.3 to the Issuer’s Current Report on Form 8-K filed with the Commission
on November 2, 2023). |
| 5. | Second Amended and Restated Limited Liability Company Agreement of TPG GP A, LLC, dated as of November
1, 2023, among TPG Inc. and the members of TPG GP A, LLC party thereto (incorporated by reference to Exhibit 10.4 to the Issuer’s
Current Report on Form 8-K, filed with the Commission on November 2, 2023). |
| 6. | Amended and Restated Exchange Agreement, dated as of November 1, 2023, among TPG Inc., TPG OpCo Holdings,
L.P., TPG Operating Group I, L.P., TPG Operating Group II, L.P., TPG Operating Group III, L.P. and each of the other persons party thereto
(incorporated by reference to Exhibit 10.2 to the Issuer’s Current Report on Form 8-K filed with the Commission on November 2, 2023). |
| 7. | Amended and Restated Investor Rights Agreement, dated as of November 1, 2023, among TPG Inc., TPG Operating
Group I, L.P., TPG Operating Group II, L.P., TPG Operating Group III, L.P., TPG Group Holdings (SBS), L.P., TPG New Holdings, LLC, TPG
Partner Holdings, L.P. and each of the other persons party thereto (incorporated by reference to Exhibit 10.1 to the Issuer’s Current
Report on Form 8-K filed with the Commission on November 2, 2023). |
| 8. | Seventh Amended and Restated Limited Partnership Agreement of TPG Operating Group II, L.P., dated as
of November 1, 2023, among TPG Holdings II-A, LLC and the limited partners of TPG Operating Group II, L.P. |
| 9. | Amended and Restated Tax Receivable Agreement, dated as of November 1, 2023, among TPG Inc., TPG OpCo
Holdings, L.P., TPG Operating Group I, L.P., TPG Operating Group II, L.P., TPG Operating Group III, L.P. and each of the other persons
party thereto (incorporated by reference to Exhibit 10.3 to the Issuer’s Current Report on Form 8-K filed with the Commission on
November 2, 2023). |
CUSIP No. 872657101 |
SCHEDULE
13D |
Page 10 of 10 |
| 10. | Employment Agreement, dated as of December 15, 2021, among TPG Global, LLC, TPG Holdings, L.P., TPG Partner Holdings, L.P., TPG Group
Advisors (Cayman), Inc. and Jon Winkelried (incorporated by reference to Exhibit 10.15 to the Company’s Annual Report on Form 10-K,
filed on March 29, 2022). |
| 11. | Underwriting Agreement, dated February 26, 2024 by and among TPG Inc., the underwriters listed in Schedule 1 thereto and the
stockholders named in Schedule 2 thereto. |
| 12. | Form of Lock-Up Letter, by and among each of the selling stockholders listed in Schedule 2 to the Underwriting Agreement and the underwriters
listed in Schedule 1 thereto (incorporated by reference to Exhibit A to Exhibit 11 to this Schedule 13D). |
Execution Version
TPG Inc.
15,526,915 Shares of Class A Common Stock
Underwriting Agreement
February 26, 2024
J.P. Morgan Securities LLC
383 Madison Avenue
New York, New York 10179
Morgan Stanley & Co. LLC
1585 Broadway
New York, New York 10036
Ladies and Gentlemen:
The stockholders named in Schedule 2 hereto (the
“Selling Stockholders”) of TPG Inc., a Delaware corporation (the “Company”), propose to sell to the underwriters
listed in Schedule 1 hereto (the “Underwriters”) an aggregate of 15,526,915 shares of Class A common stock, par value $0.001
per share (the “Class A Common Stock”), of the Company (the “Shares”), including (i) 1,582,415 issued and outstanding
shares of Class A Common Stock held by certain stockholders of the Company and (ii) 13,944,500 shares of Class A Common Stock that are
issuable upon exchange for 13,944,500 of common units (the “Common Units”) of TPG Operating Group II, L.P. (the “TPG
Operating Group”) and cancellation of a corresponding number of shares of Class B common stock, par value $0.001 per share (the
“Class B Common Stock”) of the Company. The shares of Class A Common Stock to be outstanding after giving effect to the sale
of the Shares, together with the shares of nonvoting Class A common stock, par value $0.001 per share, and the shares of Class B common
stock of the Company are hereinafter referred to as the “Common Stock.”
The Company
is a holding company of the entity serving as the general partner of the TPG Operating Group and owns Common Units of TPG Operating Group
representing approximately 23% of the Common Units, which includes Common Units to be received in exchange for Class A Common Stock in
connection with the offering as described in the Prospectus, and 100% of the interests in certain intermediate holding companies. TPG
Operating Group also issues promote units, which entitle the holder to certain distributions of performance allocations received by TPG
Operating Group (the “Promote Units” and together with the Common Units, the “TPG Operating Group Units”). The
Company, TPG Operating Group and TPG OpCo Holdings, L.P. are each referred to herein as a “Company Party” and together referred
to herein as the “Company Parties.”
For the
avoidance of doubt, it shall be understood and agreed that any and all references in this underwriting agreement (this “Agreement”)
to “subsidiaries” of the Company shall be deemed to refer to the Company and its consolidated subsidiaries.
The Company
Parties and each of the Selling Stockholders hereby confirm their agreement with the several Underwriters concerning the purchase and
sale of the Shares, as follows:
1. Registration
Statement. The Company has prepared and filed with the Securities and Exchange Commission (the “Commission”) under the
Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Securities Act”),
an automatic shelf registration statement on Form S-3 (File No. 333-277340), including a related base prospectus, relating to the Shares.
Such registration statement, as amended at the time it became effective, including the information, if any, deemed pursuant to Rule 430B
or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness (“Rule 430 Information”),
is referred to herein as the “Registration Statement”; and as used herein, the term
“Base Prospectus” means the base prospectus included in the Registration Statement (and any amendments thereto) at the time
of effectiveness, the term “Preliminary Prospectus” means any preliminary prospectus relating to the Shares filed with the
Commission pursuant to Rule 424(b) under the Securities Act, including the Base Prospectus and any preliminary prospectus supplement thereto
relating to the Shares that is used prior to the filing of the Prospectus, and the term “Prospectus” means the final prospectus
relating to the Shares filed with the Commission pursuant to Rule 424(b) under the Securities Act, including the Base Prospectus and any
final prospectus supplement thereto relating to the Shares. Any reference in this Agreement to the Registration Statement, any
Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant
to Item 12 of Form S-3 under the Securities Act, as of the effective date of the Registration Statement or the date of such Preliminary
Prospectus or the Prospectus, as the case may be, and any reference to “amend”, “amendment” or “supplement”
with respect to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any documents
filed after such date under the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder
(collectively, the “Exchange Act”) that are deemed to be incorporated by reference therein. Capitalized terms used but not
defined herein shall have the meanings given to such terms in the Registration Statement and the Prospectus.
At or prior to the Applicable Time (as defined
below), the Company had prepared the following information (collectively with the pricing information set forth on Annex A, the “Pricing
Disclosure Package”): a Preliminary Prospectus dated February 26, 2024, and each “free-writing prospectus” (as defined
pursuant to Rule 405 under the Securities Act) listed on Annex A hereto.
“Applicable Time” means 6:26 A.M.,
New York City time, on February 26, 2024.
2. Purchase
of the Shares.
(a) Each
of the Selling Stockholders agrees, severally and not jointly, as and to the extent indicated in Schedule 2 hereto, to sell the Shares
to the several Underwriters as provided in this Agreement, and each Underwriter, on the basis of the representations, warranties and agreements
set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a price per share of
$41.64 (the “Purchase Price”) from each of the Selling Stockholders the number of Shares set forth opposite their respective
names in Schedule 2.
(b) The
Selling Stockholders understand that the Underwriters intend to make a public offering of the Shares, and initially to offer the Shares
on the terms set forth in the Pricing Disclosure Package. The Selling Stockholders acknowledge and agree that the Underwriters may offer
and sell Shares to or through any affiliate of an Underwriter.
(c) Payment
for the Shares shall be made by wire transfer in immediately available funds to the account specified by Equiniti Trust Company, LLC,
as custodian (the “Custodian”) for each of the Selling Stockholders at the offices of Ropes & Gray LLP at 10:00 A.M. New
York City time on February 29, 2024, or at such other time or place on the same or such other date, not later than the fifth business
day thereafter, as the Underwriters and an Attorney-in-Fact may agree upon in writing. The time and date of such payment for the Shares
is referred to herein as the “Closing Date.”
Payment for the Shares to be purchased on the
Closing Date shall be made against delivery to the Underwriters of the Shares to be purchased on such date with any transfer taxes payable
in connection with the sale of such Shares duly paid by the Selling Stockholders. Delivery of the Shares shall be made through the facilities
of The Depository Trust Company (“DTC”) unless the Underwriters shall otherwise instruct.
(d)
Each of the Company Parties and the Selling Stockholders acknowledges and agrees that the Underwriters are acting solely in the capacity
of an arm’s length contractual counterparty to the Company Parties and the Selling Stockholders with respect to the offering of
Shares contemplated hereby (including in connection with determining the terms of the offering) and not as a financial advisor or a fiduciary
to, or an agent of, the Company Parties, the Selling Stockholders or any other person. Additionally, the Underwriters are not advising
the Company Parties, the Selling Stockholders or any other person as to any legal, tax, investment, accounting or regulatory matters in
any jurisdiction. The Company Parties and the Selling Stockholders shall consult with their own advisors concerning such matters and shall
be responsible for making their own independent investigation and appraisal of the transactions contemplated hereby, and the Underwriters
shall have no responsibility or liability to the Company Parties or the Selling Stockholders with respect thereto. Any review by the Underwriters
of the Company Parties, the transactions contemplated hereby or other matters relating to such transactions will be performed solely for
the benefit of the Underwriters and shall not be on behalf of the Company Parties or the Selling Stockholders. Moreover, the Selling Stockholders
acknowledge and agree that, although the Underwriters may be required or choose to provide certain Selling Stockholders with certain Regulation
Best Interest and Form CRS disclosures in connection with the offering, enter into a “lock-up” agreement, or sell any Shares
at the price determined in the offering, nothing set forth in such disclosures is intended to suggest that the Underwriters are making
such a recommendation.
3. Representations
and Warranties of the Company Parties. Each Company Party represents and warrants, jointly and severally, to each Underwriter and
the Selling Stockholders that:
(a) Preliminary
Prospectus. No order preventing or suspending the use of any Preliminary Prospectus has been issued by the Commission, and each Preliminary
Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the Securities
Act, and no Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, contained any untrue statement
of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; provided that the Company Parties make no representation or warranty with respect to
any statements or omissions made in reliance upon and in conformity with (i) any Selling Stockholder Information (as defined in Section
4(f)) or (ii) information relating to any Underwriter furnished to the Company in writing by such Underwriter expressly for use in any
Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information
described as such in Section 9(c) hereof.
(b) Pricing
Disclosure Package. The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing Date, will not, contain
any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading; provided that the Company Parties make no representation or warranty
with respect to any statements or omissions made in reliance upon and in conformity with (i) any Selling Stockholder Information or (ii)
information relating to any Underwriter furnished to the Company in writing by such Underwriter expressly for use in such Pricing Disclosure
Package, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described
as such in Section 9(c) hereof.
(c) Issuer
Free Writing Prospectus. Other than the Registration Statement, the Preliminary Prospectus and the Prospectus, the Company (including
its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved
or referred to and will not prepare, make, use, authorize, approve or refer to any “written communication” (as defined in
Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Shares (each such communication
by the Company or its agents and representatives (other than a communication referred to in clause (i) below) an “Issuer Free Writing
Prospectus”) other than (i) any document not constituting a prospectus pursuant to Section 2(a)(10)(a) of the Securities Act or
Rule 134 under the Securities Act, (ii) the documents listed on Annex A hereto, which constitute part of the Pricing Disclosure Package,
and (iii) each electronic road show and any other written communications approved in writing in advance by the Underwriters.
Each such Issuer Free Writing Prospectus complies in all material
respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in accordance with the Securities
Act (to the extent required thereby), does not conflict with the information contained in the Registration Statement or the Pricing Disclosure
Package, and, when taken together with the Preliminary Prospectus filed prior to the first use of such Issuer Free Writing Prospectus,
at the Applicable Time, did not, and as of the Closing Date, will not, contain any untrue statement of a material fact or omit to state
a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
provided that the Company Parties make no representation or warranty with respect to any statements or omissions made in each such
Issuer Free Writing Prospectus or Preliminary Prospectus in reliance upon and in conformity with (i) any Selling Stockholder Information
or (ii) information relating to any Underwriter furnished to the Company in writing by such Underwriter expressly for use in such Issuer
Free Writing Prospectus or Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter
consists of the information described as such in Section 9(c) hereof.
(d) Testing-the-Waters
Materials. The Company (i) has not alone engaged in any Testing-the-Waters Communications other than Testing-the-Waters Communications
with the consent of the Underwriters (x) with entities that are qualified institutional buyers (“QIBs”) within the meaning
of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501(a)(1), (a)(2), (a)(3),
(a)(7), (a)(8), (a)(9), (a)(12) or (a)(13) of Regulation D under the Securities Act (“IAIs”) or (y) with entities that the
Company reasonably believed to be QIBs or IAIs and otherwise in compliance with the requirements of Rule 163B under the Securities Act
and (ii) has not authorized anyone other than J.P. Morgan Securities LLC and TPG Capital BD, LLC to engage in Testing-the-Waters Communications.
The Company has not distributed or approved for distribution any Testing-the-Waters Communications. “Testing-the-Waters Communication”
means any oral or written communication with potential investors undertaken in reliance on Rule 163B under the Securities Act; and “Written
Testing-the-Waters Communication” means any Testing-the-Waters Communication that is a written communication within the meaning
of Rule 405 under the Act.
(e) Registration
Statement and Prospectus. The Registration Statement is an “automatic shelf registration statement” as defined under Rule
405 of the Securities Act that has been filed with the Commission not earlier than three years prior to the date hereof; and no notice
of objection of the Commission to the use of such registration statement or any post-effective amendment thereto pursuant to Rule 401(g)(2)
under the Securities Act has been received by the Company. No order suspending the effectiveness of the Registration Statement has been
issued by the Commission, and no proceeding for that purpose or pursuant to Section 8A of the Securities Act against the Company or related
to the offering of the Shares has been, to the knowledge of any Company Party, initiated or threatened by the Commission; as of the applicable
effective date of the Registration Statement and any post-effective amendment thereto, the Registration Statement and any such post-effective
amendment complied and will comply in all material respects with the Securities Act, and did not and will not contain any untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein
not misleading;
and as of the date of the Prospectus and any amendment or
supplement thereto and as of the Closing Date, the Prospectus will comply in all material respects with the Securities Act and will not
contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading; provided that the Company Parties make no representation
or warranty with respect to any statements or omissions made in reliance upon and in conformity with (i) any Selling Stockholder Information
or (ii) information relating to any Underwriter furnished to the Company in writing by such Underwriter expressly for use in the Registration
Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only such information furnished
by any Underwriter consists of the information described as such in Section 9(c) hereof.
(f) Incorporated
Documents. The documents incorporated by reference in each of the Registration Statement, the Prospectus and the Pricing Disclosure
Package, when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none
of such documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated
by reference in the Registration Statement, the Prospectus or the Pricing Disclosure Package, when such documents are filed with the Commission,
will conform in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable, and will not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading.
(g) Financial
Statements. The financial statements (including the related notes thereto) of the Company and its consolidated subsidiaries and of
AG Partner Investments, L.P. (“Angelo Gordon”) and its consolidated subsidiaries included or incorporated by reference in
each of the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the applicable
requirements of the Securities Act and the Exchange Act, as applicable, and present fairly in all material respects the financial position
of the entities indicated as of the dates indicated and the results of their operations and the changes in their cash flows for the periods
specified; such financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”)
in the United States applied on a consistent basis throughout the periods covered thereby, and any supporting schedules included or incorporated
by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus present fairly in all material respects
the information required to be stated therein; the other financial information included or incorporated by reference in each of the Registration
Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company and its consolidated
subsidiaries and Angelo Gordon and its consolidated subsidiaries, as applicable, and presents fairly in all material respects the information
shown thereby;
all disclosures included or incorporated by reference in
the Registration Statement, the Pricing Disclosure Package and the Prospectus regarding “non-GAAP financial measures” (as
such term is defined by the rules and regulations of Commission) comply in all material respects with Regulation G of the Exchange Act
and Item 10 of Regulation S-K of the Securities Act, to the extent applicable; and the pro forma financial information and the related
notes thereto included or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus
have been prepared in accordance with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and the
assumptions underlying such pro forma financial information are reasonable and are set forth in each of the Registration Statement, the
Pricing Disclosure Package and the Prospectus. The interactive data in eXtensible Business Reporting Language included or incorporated
by reference in each of the Registration Statement, the Prospectus and the Pricing Disclosure Package fairly presents the information
called for in all material respects and is prepared in accordance with the Commission’s rules and guidelines applicable thereto.
All representations in this Section 3(g) relating to Angelo Gordon’s financial statements and information are qualified in their
entirety by the Company’s knowledge.
(h) No
Material Adverse Change. Since the date of the most recent financial statements included or incorporated by reference in each of the
Registration Statement, the Pricing Disclosure Package and the Prospectus, (i) there has not been any change in the capital stock,
short-term debt or long-term debt of the Company Parties or any of their subsidiaries, or any dividend or distribution of any kind declared,
set aside for payment, paid or made by any Company Party on any class of capital stock, or any material adverse change, or any development
involving a prospective material adverse change, in or affecting the business, properties, management, financial position, stockholders’
equity or results of operations of the Company Parties and their subsidiaries taken as a whole (except for, in each case, (A) subsequent
issuances or capital stock repurchases or cancellations, if any, (i) described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus, (ii) pursuant to the TPG Inc. Omnibus Equity Incentive Plan; (iii) in connection with or as a result of exchanges
of Common Units for shares of Class A Common Stock, including any exchanges of interests in TPG Partner Holdings, L.P. for Common Units,
(iv) any issuances or cancellations by the Company of shares of Class B Common Stock or (v) any tax distributions made by the Company’s
subsidiaries in the ordinary course of business and distributions in respect of the Common Units, (B) ordinary course drawdowns or repayments
on the Company’s credit facilities, (C) other ordinary course short term indebtedness of the Company or any of its subsidiaries
or (D) ordinary course dividends to be paid on the Class A Common Stock); (ii) none of the Company Parties nor any of their subsidiaries
have entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company Parties
and their subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company
Parties and their subsidiaries taken as a whole; and (iii) neither the Company Parties nor any of their subsidiaries have sustained any
loss or interference with its business that is material to the Company Parties and their subsidiaries taken as a whole and that is either
from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action,
order or decree of any court or arbitrator or governmental or regulatory authority, except in each of the foregoing clauses (i), (ii)
or (iii) as otherwise disclosed in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus.
(i) Organization
and Good Standing. The Company Parties and each “significant subsidiary” (as defined below) have been duly organized and
are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business
and are in good standing in each jurisdiction in which their respective ownership or lease of property or the conduct of their respective
businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct
the businesses in which they are engaged, except where the failure to be so qualified or in good standing or have such power or authority
would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the business, properties, management,
financial position, stockholders’ equity or results of operations of the Company Parties and their subsidiaries taken as a whole
or on the performance by the Company Parties of their obligations under this Agreement (a “Material Adverse Effect”). The
Company Parties do not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries
listed in Exhibit 21.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, except any such entities
that would not, individually or in the aggregate, constitute a “significant subsidiary” as such term is defined under Rule
1.02(w) of Regulation S-X under the Exchange Act.
(j) Capitalization.
Each of the Company Parties has an authorized capitalization as set forth in each of the Registration Statement, the Pricing
Disclosure Package and the Prospectus under the heading “Capitalization”; and all the
outstanding shares of capital stock of the Company (including the Shares to be sold by the Selling Stockholders) and the outstanding TPG
Operating Group Units have been duly and validly authorized and issued and are fully paid any non-assessable and are not subject to any
pre-emptive or similar rights; except as described in or expressly contemplated by the Registration Statement, the Pricing Disclosure
Package and the Prospectus, there are no outstanding rights (including, without limitation, pre-emptive rights), warrants or options to
acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company Parties
or any of their subsidiaries, or any contract, commitment, agreement, understanding or arrangement or any kind relating to the issuance
of any capital stock of the Company Parties or any such subsidiary, any such convertible or exchangeable securities or any such rights,
warrants or options; the capital stock of the Company and the TPG Operating Group Units conforms in all material respects to the description
thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and all the outstanding shares or
capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company Parties have been duly and validly
authorized and issued, are fully paid and non-assessable and are owned directly or indirectly by the Company Parties, free and clear of
any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party.
(k) Equity
Awards. With respect to the equity or equity-based awards granted on or before the Closing Date pursuant to the equity compensation
plans of the Company Parties and their subsidiaries (such awards, the “Equity Awards” and such plans, the “Equity Plans”),
(i) each grant of an Equity Award was duly authorized as of no later than the date on which the grant of such Equity Award was by its
terms to be effective (the “Grant Date”) by all necessary corporate action, including, as applicable, approval by the board
of directors, board of managers or similar governing body of the applicable Company Party (or a duly constituted and authorized committee
thereof) and any required stockholder or member approval by the necessary number of votes or written consents, and, to the knowledge of
the Company Parties, the award agreement governing such grant (if any) was duly executed and delivered by the applicable Company Party,
(ii) each such grant was made in accordance with the terms of the Equity Plans, the Exchange Act and all other applicable laws and regulatory
rules or requirements, including the rules of the Nasdaq Global Select Market (the “Exchange”) and any other exchange on which
Company securities are traded, in each case, to the extent applicable, and (iii) to the extent required to be disclosed in the financial
statements contained or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the
Prospectus, each such grant was properly accounted for in accordance with GAAP in the financial
statements (including the related notes) of the applicable Company Party contained or incorporated by reference in each of the Registration
Statement, the Pricing Disclosure Package and the Prospectus and disclosed in the applicable
filings with the Commission in accordance with the Exchange Act, except in each case, with respect to the events or conditions set forth
in (i) through (iii) hereof, as would not, individually or in the aggregate, have a Material Adverse Effect.
(l) Due
Authorization. Each Company Party has full right, power and authority to execute and deliver this Agreement and to perform its obligations
hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and
the consummation by it of the transactions contemplated hereby has been duly and validly taken.
(m) Underwriting
Agreement. This Agreement has been duly authorized, executed and delivered by each Company Party.
(n) [Reserved].
(o) No
Violation or Default. None of the Company Parties nor any of their subsidiaries is (i) in
violation of its respective charter or by-laws or similar organizational documents; (ii) in default, and no event has occurred that,
with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition
contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which a Company Party or any of
its subsidiaries is a party or by which a Company Party or any of its subsidiaries is bound or to which any property or asset of a Company
Party or any of its subsidiaries is subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of
any court or arbitrator or governmental or regulatory authority having jurisdiction over the Company Parties or any of their subsidiaries,
except, in the case of clauses (ii) and (iii) above, for any such default or violation that would not reasonably be expected, individually
or in the aggregate, to have a Material Adverse Effect.
(p) No
Conflicts. The execution, delivery and performance by each Company Party of this Agreement, and the consummation of the transactions
contemplated by this Agreement or the Pricing Disclosure Package and the Prospectus will not (i) conflict with or result in a breach or
violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration
of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or asset of a Company Party or
any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which
a Company Party or any of its subsidiaries is a party or by which a Company Party or any of its subsidiaries is bound or to which any
property, right or asset of a Company Party or any of its subsidiaries is subject, (ii) result in any violation of the provisions of the
charter or by-laws or similar organizational documents of a Company Party or any of its subsidiaries or (iii) result in the violation
of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority having
jurisdiction over a Company Party or any of its subsidiaries, except, in the case of clauses (i) and (iii) above, for any such conflict,
breach, violation, default, lien, charge or encumbrance that would not reasonably be expected, individually or in the aggregate, to have
a Material Adverse Effect.
(q) No
Consents Required. No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator or
governmental or regulatory authority is required for the execution, delivery and performance by each Company Party of this Agreement and
the consummation of the transactions contemplated by this Agreement, except for (i) the
registration of the Shares under the Securities Act, (ii) such consents, approvals, authorizations, orders and registrations or
qualifications as may be required by the Financial Industry Regulatory Authority, Inc. (“FINRA”), the Exchange and under applicable
state securities laws in connection with the purchase and distribution of the Shares by the Underwriters, (iii) any consent, approval,
authorization, order or registration qualification received by any Company Party as of the date hereof, or (iv) where the failure to obtain
any such consent, approval, authorization, order or registration or qualification would not reasonably be expected, individually or in
the aggregate, to materially adversely affect the ability of the Company Parties to consummate the transactions contemplated by this Agreement.
(r) Legal
Proceedings. Except as described in each of the Registration Statement, the Pricing Disclosure Package and
the Prospectus, there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries
or proceedings (“Actions”) pending to which a Company Party or any of its subsidiaries is or may be a party or to which any
property of a Company Party or any of its subsidiaries is or may be the subject that, individually or in the aggregate, if determined
adversely to a Company Party or any of its subsidiaries, could reasonably be expected to have a Material Adverse Effect;
and to the knowledge of the Company Parties, no such Actions
are threatened or contemplated by any governmental or regulatory authority or threatened by others, except as would not reasonably be
expected, individually or in the aggregate, to have a Material Adverse Effect; and (i) there are no current or pending Actions that are
required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that
are not so described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus and (ii) there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be
filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package or the Prospectus
that are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus.
(s) Independent
Accountants. Deloitte & Touche LLP, who has certified certain financial statements of the Company and its subsidiaries, is an
independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations
adopted by the Commission and the Public Company Accounting Oversight Board (United States) (the “PCAOB”) and as required
by the Securities Act; PricewaterhouseCoopers LLP, who has audited/reviewed certain financial statements of Angelo Gordon and its subsidiaries,
are independent public accountants within the meaning of Rule 101 of the Code of Professional Conduct of the American Institute of Certified
Public Accountants and its interpretations and rulings thereunder.
(t) Title
to Real and Personal Property. Each Company Party and its subsidiaries have good and marketable title in fee simple to, or have valid
rights to lease or otherwise use, all items of real and personal property that are material to the respective businesses of each Company
Party and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except
those that (i) do not materially interfere with the use made and proposed to be made of such property by the Company Parties and
their subsidiaries or (ii) could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.
(u) Intellectual
Property. (i) Each Company Party and its subsidiaries own or have the right to use all patents, patent applications, trademarks, service
marks, trade names, trademark registrations, service mark registrations, domain names and other source indicators, copyrights and copyrightable
works, know-how, trade secrets, systems, procedures, proprietary or confidential information and all other worldwide intellectual property,
industrial property and proprietary rights (collectively, “Intellectual Property”) used in the conduct of their respective
businesses; (ii) each Company Party’s and its subsidiaries’ conduct of their respective businesses does not infringe, misappropriate
or otherwise violate any Intellectual Property of any person; (iii) none of the Company Parties nor its subsidiaries has received any
written notice of any claim relating to Intellectual Property; and (iv) to the knowledge of the Company Parties, the Intellectual Property
of any Company Party or its subsidiaries is not being infringed, misappropriated or otherwise violated by any person, except, for in all
cases, where the failure to own or possess such rights would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect.
(v) No
Undisclosed Relationships. No relationship, direct or indirect, exists between or among any Company Party or any of its subsidiaries,
on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of any Company Party or any of its
subsidiaries, on the other, that is required by the Securities Act to be described in each of the Registration Statement and the Prospectus
and that is not so described in such documents and in the Pricing Disclosure Package.
(w) Investment
Company Act. No Company Party is required to register as an “investment company” within the meaning of the Investment
Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Investment Company
Act”).
(x) Investment
Advisers Act and Other Applicable Laws. Each Company Party and its subsidiaries that are required to be in compliance with, or registered,
licensed or qualified pursuant to, the Investment Advisers Act of 1940, as amended, and the rules and regulations promulgated thereunder
(collectively, the “Advisers Act”), the Investment Company Act, the Exchange Act, the Commodity Exchange Act and the rules
and regulations promulgated thereunder or any other applicable law, are in compliance with, or registered, licensed or qualified pursuant
to, such laws, rules and regulations (and such registration, license or qualification is in full force and effect), to the extent applicable,
except as otherwise disclosed in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus or where the failure
to be in such compliance or so registered, licensed or qualified would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect.
(y) Taxes.
Each Company Party and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns required to
be paid or filed through the date hereof, except for any taxes that are not yet due or are currently being contested in good faith and
for which adequate reserves have been provided in accordance with GAAP, or where failure to pay or file would not, individually or in
the aggregate reasonably be expected to have a Material Adverse Effect; and except as otherwise disclosed in each of the Registration
Statement, the Pricing Disclosure Package and the Prospectus, there is no tax deficiency
that has been, or could reasonably be expected to be, asserted against a Company Party or any of its subsidiaries or any of their respective
properties or assets, except those that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.
(z) Licenses
and Permits. Each Company Party and its subsidiaries possess all licenses, sub-licenses, certificates, permits and other authorizations
issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory
authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses
as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the failure to possess
or make the same would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; and except as
described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus,
none of the Company Parties nor any of their subsidiaries has received notice of any revocation or modification of any such license, sub-license,
certificate, permit or authorization or has any reason to believe that any such license, sub-license, certificate, permit or authorization
will not be renewed in the ordinary course.
(aa) Fund
Agreements. To the knowledge of the Company Parties, none of the Company Parties nor any of their subsidiaries that acts as a general
partner or managing member (or in a similar capacity) or as an investment adviser or investment manager of any TPG Fund has performed
any act or otherwise engaged in any conduct that would prevent a Company Party or any of its subsidiaries, as the case may be, from benefiting
from any exculpation clause or other limitation of liability available to it under the terms of the management agreement or advisory agreement,
as applicable, between the applicable Company Party or subsidiary, as the case may be, and the TPG Fund except, in each case, as would
not, singly or in the aggregate, reasonably be expected to have a Material Adverse Effect.
(bb) No
Labor Disputes. No labor disturbance by or dispute with employees of the Company Parties or any of their subsidiaries exists or, to
the knowledge of the Company Parties, is contemplated or threatened, and none of the Company Parties is aware of any existing or
imminent labor disturbance by, or dispute with, the employees of any of its or its subsidiaries’ principal suppliers, contractors
or customers, except as would not reasonably be expected to have a Material Adverse Effect. None
of the Company Parties nor any of its subsidiaries have received any notice of cancellation or termination with respect to any collective
bargaining agreement to which it is a party, except as would not reasonably be expected, individually or in the aggregate, to have a Material
Adverse Effect.
(cc) Certain
Environmental Matters. (i) Each Company Party and its subsidiaries (x) are in compliance with all, and have not violated any, applicable
federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders
and other legally enforceable requirements relating to pollution or the protection of human health or safety, the environment, natural
resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, “Environmental Laws”); (y) have
received and are in compliance with all, and have not violated any, permits, licenses, certificates or other authorizations or approvals
required of them under any Environmental Laws to conduct their respective businesses; and (z) have not received notice of any actual or
potential liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including for
the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, and
have no knowledge of any event or condition that would reasonably be expected to result in any such notice;
(ii) there are no costs or liabilities associated with Environmental
Laws of or relating to any Company Party or its subsidiaries, except in the case of each of (i) and (ii) above, for any such matter as
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii) except as described in
each of the Pricing Disclosure Package and the Prospectus, (x) there is no proceeding that is pending, or that is known to be contemplated,
against a Company Party or any of its subsidiaries under any Environmental Laws in which a governmental entity is also a party, other
than such proceeding regarding which it is reasonably believed no monetary sanctions of $300,000 or more will be imposed and (y) none
of the Company Parties nor its subsidiaries is aware of any facts or issues regarding compliance with Environmental Laws that would reasonably
be expected to have a material impact on the earnings or capital expenditures of any Company Party.
(dd) Compliance
with ERISA. (i) Each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974,
as amended (“ERISA”), for which any Company Party or any member of its “Controlled Group” (defined as any entity,
whether or not incorporated, that is under common control with such Company Party within the meaning of Section 4001(a)(14) of ERISA or
any entity that would be regarded as a single employer with a Company Party under Section 414(b),(c),(m) or (o) of the Internal Revenue
Code of 1986, as amended (the “Code”)) would have any liability (each, a “Plan”) has been maintained in compliance
with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and
the Code; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect
to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (iii) for each Plan that is subject
to the funding rules of Section 412 of the Code or Section 302 of ERISA, no Plan has failed (whether or not waived), or is reasonably
expected to fail, to satisfy the minimum funding standards (within the meaning of Section 302 of ERISA or Section 412 of the Code) applicable
to such Plan; (iv) no Plan is, or is reasonably expected to be, in “at risk status” (within the meaning of Section 303(i)
of ERISA) and no Plan that is a “multiemployer plan” within the meaning of Section 4001(a)(3) of ERISA is in “endangered
status” or “critical status” (within the meaning of Sections 304 and 305 of ERISA) (v) the fair market value of the
assets of each Plan is equal to or exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions
used to fund such Plan); (vi) no “reportable event” (within the meaning of Section 4043(c) of ERISA and the regulations promulgated
thereunder) has occurred or is reasonably expected to occur; (vii) each Plan that is intended to be qualified under Section 401(a) of
the Code is so qualified, and nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification;
(viii) none of the Company Parties or any member of the Controlled Group has incurred, or reasonably expects to incur, any liability under
Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guarantee Corporation, in the ordinary course
and without default) in respect of a Plan (including a “multiemployer plan” within the meaning of Section 4001(a)(3) of ERISA);
and (ix) none of the following events has occurred or is reasonably
likely to occur: (A) a material increase in the aggregate amount of contributions required to be made to all Plans by a Company Party
or its Controlled Group affiliates in the current fiscal year of such Company Party and its Controlled Group affiliates compared to the
amount of such contributions made in such Company Party’s and its Controlled Group affiliates’ most recently completed fiscal
year; or (B) a material increase in the Company Parties’ and their subsidiaries’ “accumulated post-retirement benefit
obligations” (within the meaning of Accounting Standards Codification Topic 715-60) compared to the amount of such obligations in
the Company Parties and their subsidiaries’ most recently completed fiscal year, except in each case with respect to the events
or conditions set forth in (i) through (ix) hereof, as would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect.
(ee) Disclosure Controls. The
Company maintains a system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) of the Exchange Act) that
complies with the requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the
Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods
specified in the Commission’s rules and forms, including controls and procedures designed to ensure that such information is accumulated
and communicated to management as appropriate to allow timely decisions regarding required disclosure. The Company has carried out evaluations
of the effectiveness of its disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act. This Section 3(ee) is qualified
by the Company’s exclusion of the effectiveness of the Company’s internal control over financial reporting related to Angelo
Gordon (as defined in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023), as disclosed in the
Pricing Disclosure Package and the Prospectus.
(ff) Accounting
Controls. The Company maintains systems of “internal control over financial reporting” (as defined in Rule 13a-15(f) of
the Exchange Act) that comply with the requirements of the Exchange Act applicable to the Company and have been designed by, or under
the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP. The Company maintains internal accounting controls sufficient to provide reasonable assurance that (i)
transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as
necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to
assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
Except as disclosed in each of the Registration Statement, the Pricing Disclosure Package
and the Prospectus, no Company Party is aware of any material weaknesses in the Company’s and its subsidiaries’ internal controls.
The auditors have been
advised of: (i) all deficiencies in the design or operation of internal controls over financial reporting which the Company believes to
be significant deficiencies or material weaknesses, which have adversely affected or are reasonably likely to adversely affect the Company’s
and its subsidiaries’ ability to record, process, summarize and report financial information; and (ii) any fraud, whether or not
material, that involves management or other employees who have a significant role in the Company’s and its subsidiaries’ internal
controls over financial reporting. This Section 3(ff) is qualified by the Company’s exclusion of the effectiveness of the
Company’s internal control over financial reporting related to Angelo Gordon (as defined in the Company’s Annual Report on
Form 10-K for the fiscal year ended December 31, 2023), as disclosed in the Pricing Disclosure Package and the Prospectus.
(gg) [Reserved].
(hh) Insurance.
Each Company Party and its subsidiaries have insurance covering their respective properties, operations, personnel and businesses,
which insurance is in amounts and insures against such losses and risks as are reasonably adequate and customary for the businesses in
which they are engaged; and none of the Company Parties nor any of their subsidiaries has (i) received notice from any insurer or agent
of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance
or (ii) any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to
obtain substantially or materially similar coverage at reasonable cost from similar insurers as may be necessary to continue its business.
(ii) Cybersecurity;
Data Protection. (i) Each Company Party and its subsidiaries’ information technology assets and equipment, computers, systems,
networks, hardware, software, websites, applications, and databases (collectively, “IT Systems”) are adequate for,
and operate and perform as required in connection with the operation of the business of such Company Party and its subsidiaries as currently
conducted, and are, to the knowledge of the Company Parties, free and clear of all bugs, errors, defects, Trojan horses, time bombs, malware
and other corruptants; (ii) each Company Party and its subsidiaries have implemented and maintained commercially reasonable controls,
policies, procedures and safeguards to maintain and protect the integrity, continuous operation, redundancy and security of all IT Systems
and data (including all personal, personally identifiable, sensitive, confidential or regulated data (“Personal Data”)) used
in connection with their businesses, and there have been no breaches, violations, outages or unauthorized uses of or accesses to same,
except for those that have been remedied without cost or liability or the duty to notify any other person, nor any incidents under internal
review or investigations relating to the same; (iii) each Company Party and its subsidiaries are presently in compliance with all applicable
laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority,
internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection
of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification;
and (iv) each Company Party and its subsidiaries have taken
all necessary actions to comply with the European Union General Data Protection Regulation and have taken all necessary actions to prepare
to comply with all other applicable laws and regulations with respect to Personal Data that have been announced as of the date hereof
as becoming effective within 12 months after the date hereof, and for which any non-compliance with same would be reasonably likely to
create a liability, as soon they take effect, except as would not, in the case of each of clause (i), (ii), (iii) and (iv), reasonably
be expected, individually or in the aggregate, to have a Material Adverse Effect.
(jj) No
Unlawful Payments. None of the Company Parties nor any of its subsidiaries nor any director or officer of a Company Party or
any of its subsidiaries or, to the knowledge of the Company Parties, any employee, agent, affiliate or other person associated with or
acting on behalf of a Company Party or any of its subsidiaries has (i) used any corporate funds for any unlawful contribution, gift, entertainment
or other unlawful expense relating to political activity; (ii) made or taken an act in furtherance of an offer, promise or authorization
of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned
or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of
the foregoing, or any political party or party official or candidate for political office; (iii) violated or is in violation of any provision
of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating
Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the
United Kingdom or any other applicable anti-bribery or anti-corruption law; or (iv) made, offered, agreed, requested or taken an act in
furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback
or other unlawful or improper payment or benefit. Each Company Party and its subsidiaries have instituted, maintain and enforce, and will
continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and
anti-corruption laws.
(kk) Compliance with Anti-Money
Laundering Laws. The operations of each Company Party and its subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company Parties or any of their subsidiaries
conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered
or enforced by any governmental agency (collectively, the “Anti-Money Laundering Laws”) and no action, suit or proceeding
by or before any court or governmental agency, authority or body or any arbitrator involving a Company Party or any of its subsidiaries
with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company Parties, threatened.
(ll) No Conflicts with Sanctions
Laws. None of the Company Parties nor any of their subsidiaries, directors or officers, nor, to the knowledge of the Company Parties,
any employee, agent, affiliate or other person associated with or acting on behalf of a Company Party or any of its subsidiaries is currently
the subject or the target of any sanctions administered or enforced by the U.S. government, (including, without limitation, the Office
of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”) or the U.S. Department of State and including, without
limitation, the designation as a “specially designated national” or “blocked person”), the United Nations Security
Council (“UNSC”), the European Union, or His Majesty’s Treasury (“HMT”) (collectively, “Sanctions”),
nor is a Company Party or any of its subsidiaries located, organized or resident in a country or territory that is the subject or target
of Sanctions, including, as of the date of this Agreement, the Crimea, Zaporizhzhia and Kherson regions of Ukraine, the so-called Donetsk
People’s Republic, the so-called Luhansk People’s Republic, Cuba, Iran, North Korea and Syria (each, a “Sanctioned Country”);
and no Company Party will directly, or to the knowledge of the Company Parties, indirectly, use the proceeds of the offering of the Shares
hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity
(i) to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject
or target of Sanctions, (ii) to fund or facilitate any activities of or business in any Sanctioned Country or (iii) in any other manner
that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor,
investor or otherwise) of Sanctions. For the past five years, the Company Parties and their subsidiaries have not knowingly engaged in
and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or
was the subject or the target of Sanctions or with any Sanctioned Country.
(mm) No Restrictions on Subsidiaries.
No subsidiary of a Company Party is currently prohibited, directly or indirectly, under any agreement or other instrument to which it
is a party or is subject, from paying any dividends to such Company Party, from making any other distribution on such subsidiary’s
capital stock or similar ownership interest, from repaying to such Company Party any loans or advances to such subsidiary from such Company
Party or from transferring any of such subsidiary’s properties or assets to such Company Party or any other subsidiary of such Company
Party, except as disclosed in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus or as would not reasonably
be expected to materially reduce the distributions to be received by the Company Parties, taken as a whole, from their subsidiaries.
(nn) No Broker’s Fees. Except
as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, none of the Company Parties nor any of
their respective subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that
would give rise to a valid claim against any of them or any Underwriter for a brokerage commission, finder’s fee or like payment
in connection with the offering and sale of the Shares
(oo) No
Registration Rights. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, no person
has the right to require a Company Party or any of their subsidiaries to register any securities for sale under the Securities Act by
reason of the filing of the Registration Statement with the Commission or, to the knowledge of the Company, the sale of the Shares to
be sold by the Selling Stockholders hereunder.
(pp) No
Stabilization. Except for the appointment of the Underwriters, who may engage in stabilization activities and as to whose actions
the Company Parties make no representation or warranty, none of the Company Parties nor any of their subsidiaries or affiliates has taken,
directly or indirectly, any action designed to or that could reasonably be expected to cause or
result in any stabilization or manipulation of the price of the Shares.
(qq) [Reserved].
(rr) Forward-Looking
Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act) included or incorporated by reference in any of the Registration Statement, the Pricing Disclosure Package or the Prospectus has
been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.
(ss) Statistical
and Market Data. Nothing has come to the attention of the Company Parties that has caused the Company Parties to believe that the
statistical and market-related data included or incorporated by reference in each of the Registration Statement, the Pricing Disclosure
Package and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects.
(tt) Sarbanes-Oxley Act. There
is and has been no failure on the part of the Company or any of the Company’s directors or officers, in their capacities as such,
to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection
therewith, including Section 402 related to loans and Sections 302 and 906 related to certifications, to the extent compliance is required
as of the date of this Agreement.
(uu) Status under the Securities
Act. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that
the Company or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Securities Act)
of the Shares and at the date hereof, the Company was not and is not an “ineligible issuer,” and is a well-known seasoned
issuer, in each case as defined in Rule 405 under the Securities Act. The Company has paid the registration fee for this offering pursuant
to Rule 456(b)(1) under the Securities Act or will pay such fee within the time period required by such rule (without giving effect to
the proviso therein) and in any event prior to the Closing Date.
4. Representations
and Warranties of the Selling Stockholders. Each of the Selling Stockholders, severally and not jointly, represents and warrants to
each Underwriter and the Company Parties that:
(a) Required
Consents; Authority. All consents, approvals, authorizations and orders necessary for the execution and delivery by such Selling Stockholder
of this Agreement and the Power of Attorney (as defined below) and the Custody Agreement (as defined below) hereinafter referred to, and
for the sale and delivery of the Shares to be sold by such Selling Stockholder hereunder, have been obtained; and such Selling Stockholder
has full right, power and authority (if such Selling Stockholder is not a natural person) to enter into this Agreement, the Power of Attorney
and the Custody Agreement and to sell, assign, transfer and deliver the Shares to be sold by such Selling Stockholder hereunder; this
Agreement, the Power of Attorney and the Custody Agreement have each been duly authorized (if such Selling Stockholder is not a natural
person), executed and delivered by or on behalf of such Selling Stockholder and are valid and binding agreements of such Selling Stockholder,
assuming that this Agreement has been duly authorized, executed and delivered by the other parties hereto.
(b) No
Conflicts. The execution, delivery and performance by, or on behalf of, as applicable, such Selling Stockholder of this Agreement,
the Power of Attorney and the Custody Agreement, the sale of the Shares to be sold by such Selling Stockholder and the consummation by
such Selling Stockholder of the transactions contemplated herein or therein will not (i) conflict with or result in a breach or violation
of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result
in the creation or imposition of any lien, charge or encumbrance upon any property, right or asset of such Selling Stockholder pursuant
to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which such Selling Stockholder is a party
or by which such Selling Stockholder is bound or to which any of the property, right or asset of such Selling Stockholder that is not
a natural person is subject, (ii) result in any violation of the provisions of the charter or by-laws or similar organizational documents
of such Selling Stockholder or (iii) result in the violation of any law or statute or any judgment, order, rule or regulation of any court
or arbitrator or governmental or regulatory agency having jurisdiction over such Selling Stockholder, except in the cases of clause (i)
and (iii), as would not, individually or in the aggregate, have a material adverse effect on the ability of such Selling Stockholder to
consummate the transactions contemplated by this Agreement.
(c) Title
to Shares. Such Selling Stockholder has good and valid title to, or a valid “security entitlement” within the meaning
of Section 8-102 of the New York Uniform Commercial Code, as amended (the “UCC”) in respect of, the Shares to be sold at the
Closing Date by such Selling Stockholder hereunder, free and clear of all liens, encumbrances, equities or adverse claims; such Selling
Stockholder will have, immediately prior to the Closing Date good and valid title to, or a valid “security entitlement” within
the meaning of Section 8-102 of the UCC in respect of, the Shares to be sold at the Closing Date by such Selling Stockholder, free and
clear of all liens, encumbrances, equities or adverse claims;
and, such Selling Stockholder has a security entitlement (within
the meaning of Section 8-102(a)(17) of the UCC) to the Shares maintained in a securities account on the books of DTC free and clear of
any action that may be asserted based on an adverse claim with respect to such security entitlement, and assuming that each Underwriter
acquires its interest in the Shares it has purchased without notice of any adverse claim (within the meaning of Section 8-105 of the UCC),
upon the credit of such Shares to the securities account of such Underwriter maintained with DTC and payment therefor by such Underwriter,
as provided herein, such Underwriter will have acquired a security entitlement to such securities, and no action based on any adverse
claim may be asserted against such Underwriter with respect to such security entitlement.
(d) No
Stabilization. Such Selling Stockholder has not taken and will not take, directly or indirectly, any action designed to or that could
reasonably be expected to cause or result in any stabilization or manipulation of the price of the Shares.
(e) Lock-up
Agreement. Such Selling Stockholder has delivered to the Underwriters an executed lock-up agreement in substantially the form attached
hereto as Exhibit A.
(f) Pricing
Disclosure Package. The Pricing Disclosure Package, at the Applicable Time did not, and as of the Closing Date, will not, contain
any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading; provided that such Selling Stockholder makes no representation
or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter
furnished to the Company in writing by such Underwriter expressly for use in such Pricing Disclosure Package, it being understood and
agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 9(c) hereof,
provided further that, the representations and warranties set forth in this paragraph 4(f) are limited in all respects to statements
or omissions made in reliance upon and in conformity with the information relating to such Selling Stockholder furnished to the Company
Parties in writing by or on behalf of such Selling Stockholder expressly for use in the Pricing Disclosure Package, it being understood
and agreed that for purposes of this Agreement, the only information furnished by such Selling Stockholder consists of the name of the
Selling Stockholder, the number of offered shares and the address and other information with respect to such Selling Stockholder (excluding
percentages) which appear in each of the Registration Statement, Pricing Disclosure Package or the Prospectus in the table (and corresponding
footnotes) under the caption “Principal and Selling Stockholders” (such information the “Selling Stockholder Information”).
(g) Registration
Statement and Prospectus. As of the applicable effective date of the Registration Statement and any post-effective amendment thereto,
the Registration Statement and any such post-effective amendment complied and will comply in all material respects with the Securities
Act, and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement
thereto and as of the Closing Date, the Prospectus will not contain any untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
provided that such Selling Stockholder makes no representation
or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter
furnished to the Company in writing by such Underwriter expressly for use in the Registration Statement, the
Pricing Disclosure Package and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the
only such information furnished by any Underwriter consists of the information described as such in Section 9(c) hereof, provided further
that, the representations and warranties set forth in this Section 4(g) are limited in all respects to statements or omissions made in
reliance upon and in conformity with the information relating to such Selling Stockholder furnished to the Company Parties in writing
by or on behalf of such Selling Stockholder expressly for use in the Registration Statement and Prospectus, it being understood and agreed
that for purposes of this Agreement, the only information furnished by the Selling Stockholder consists of the Selling Stockholder Information.
(h) [Reserved].
(i) No
Unlawful Payments. Neither such Selling Stockholder nor (if such Selling Stockholder is not a natural person) any of its subsidiaries,
nor any director, officer or employee of such Selling Stockholder or (if such Selling Stockholder is not a natural person) any of its
subsidiaries nor, to the knowledge of such Selling Stockholder, any agent, affiliate or other person associated with or acting on behalf
of such Selling Stockholder or (if such Selling Stockholder is not a natural person) any of its subsidiaries has (i) used any corporate
funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made or taken
an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic
government official or employee, including of any government-owned or controlled entity or of a public international organization, or
any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate
for political office; (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or
any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business
Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption
law; or (iv) made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including,
without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. Such Selling Stockholder
and its subsidiaries (if such Selling Stockholder is not a natural person) have instituted, maintain and enforce, and will continue to
maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption
laws.
(j) Compliance
with Anti-Money Laundering Laws. The operations of such Selling Stockholder and its subsidiaries (if such Selling Stockholder is not
a natural person) are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements,
including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, Organised and Serious Crimes Ordinance (Chapter
455 of the Laws of Hong Kong) and the Anti-Money Laundering and Counter-Terrorist Financing (Financial Institutions) Ordinance (Chapter
615 of the Laws of Hong Kong) and the applicable money laundering statutes of all jurisdictions where such Selling Stockholder or any
of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines
issued, administered or enforced by any governmental agency (collectively, the “Selling Stockholder Anti-Money Laundering Laws”),
and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving such Selling
Stockholder or any of its subsidiaries with respect to the Selling Stockholder Anti-Money Laundering Laws is pending or, to the knowledge
of such Selling Stockholder, threatened.
(k) No
Conflicts with Sanctions Laws. Neither such Selling Stockholder nor (if such Selling Stockholder is not a natural person) any of its
subsidiaries, directors or officers nor, to the knowledge of such Selling Stockholder, any employee, agent, affiliate or other person
associated with or acting on behalf of such Selling Stockholder or (if such Selling Stockholder is not a natural person) any of its subsidiaries
is currently the subject or the target of any Sanctions, nor is such Selling Stockholder or (if such Selling Stockholder is not a natural
person) any of its subsidiaries located, organized or resident in a Sanctioned Country; and such Selling Stockholder will not directly
or, to the knowledge of such Selling Stockholder, indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute
or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate
any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions,
(ii) to fund or facilitate any activities of or business in any Sanctioned Country or (iii) in any other manner that will result in a
violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise)
of Sanctions. For the past five years, such Selling Stockholder and (if such Selling Stockholder is not a natural person) its subsidiaries
have not knowingly engaged in, are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing
or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.
(l) Organization
and Good Standing. Such Selling Stockholder (if such Selling Stockholder is not a natural person) has been duly organized and is validly
existing and in good standing under the laws of its jurisdiction of organization.
(m) ERISA.
Such Selling Stockholder is not (i) an employee benefit plan subject to Title I of ERISA, (ii) a plan or account subject to Section 4975
of the Code or (iii) an entity deemed to hold “plan assets” of any such plan or account under Section 3(42) of ERISA, 29 C.F.R.
2510.3-101, or otherwise.
(n) Custody
Agreement and Power of Attorney. The Shares to be sold by such Selling Stockholder hereunder have been placed in custody under a Custody
Agreement relating to such Shares (the “Custody Agreement”), duly executed and delivered by an Attorney-in-Fact, on behalf
of such Selling Stockholder, to the Custodian, and such Selling Stockholder has duly executed and delivered a Power of Attorney, in the
form heretofore furnished to you (the “Power of Attorney”) appointing each of Jack Weingart, Bradford Berenson and Martin
Davidson as such Selling Stockholder’s attorney-in-fact (“Attorney-in-Fact”), with authority to execute and deliver
this Agreement on behalf of such Selling Stockholder, to determine the purchase price to be paid by the Underwriters to the Selling Stockholders
as provided in Section 2 hereof, to authorize the delivery of the Shares to be sold by such Selling Stockholder hereunder and otherwise
to act on behalf of such Selling Stockholder in connection with the transactions contemplated by this Agreement and the Custody Agreement,
in each case subject to the limitations set forth in such agreements and the Power of Attorney.
5. Further
Agreements of the Company Parties. Each of the Company Parties, jointly and severally, covenants and agrees with each Underwriter
that:
(a) Required
Filings. The Company will file the final Prospectus with the Commission within the time periods specified by Rule 424(b) and Rule
430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities
Act; and the Company will file promptly all reports and any definitive proxy or information statements required to be filed by the Company
with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for
so long as the delivery of a prospectus is required in connection with the offering or sale of the Shares; and the Company will furnish
copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the Underwriters in New York
City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the
Underwriters may reasonably request. The Company will pay the registration fee for this offering within the time period required by Rule
456(b)(1) under the Securities Act (without giving effect to the proviso therein) and in any event prior to the Closing Date.
(b) Delivery
of Copies. The Company will deliver, without charge, (i) to the Underwriters, copies of the Registration Statement as originally filed
and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference therein;
and (ii) to each Underwriter (A) a conformed copy of the Registration Statement as originally filed and each amendment thereto (without
exhibits) and (B) during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all amendments
and supplements thereto and documents incorporated by reference therein) and each Issuer Free Writing Prospectus as the Underwriters may
reasonably request.
As used herein, the term “Prospectus Delivery Period”
means such period of time after the first date of the public offering of the Shares as in the opinion of counsel for the Underwriters
a prospectus relating to the Shares is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities
Act) in connection with sales of the Shares by any Underwriter or dealer.
(c) Amendments
or Supplements, Issuer Free Writing Prospectuses. Before making, preparing, using, authorizing, approving, referring to or filing
any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing Disclosure
Package or the Prospectus, whether before or after the time that the Registration Statement becomes effective, the Company will furnish
to the Underwriters and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for
review and will not make, prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such
proposed amendment or supplement to which the Underwriters reasonably object.
(d) Notice
to the Underwriters. The Company will advise the Underwriters promptly, and confirm such advice in writing, (i) when any amendment
to the Registration Statement has been filed or becomes effective; (ii) when any supplement to the Pricing Disclosure Package, the Prospectus,
any Issuer Free Writing Prospectus, any Testing-the-Waters Communications or any amendment to the Prospectus or any Issuer Free Writing
Prospectus has been filed or distributed; (iii) of any request by the Commission for any amendment to the Registration Statement or any
amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or
any other request by the Commission for any additional information including, but not limited to, any request for information concerning
any Testing-the-Waters Communication; (iv) of the issuance by the Commission or any other governmental or regulatory authority of any
order suspending the effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, the
Prospectus, any Pricing Disclosure Package, any Issuer Free Writing Prospectus or any Testing-the-Waters Communications or the initiation
or threatening of any proceeding for that purpose or pursuant to Section 8A of the Securities Act; (v) of the occurrence of any event
or development within the Prospectus Delivery Period as a result of which the Prospectus, any of the Pricing Disclosure Package, any Issuer
Free Writing Prospectus or any Testing-the-Waters Communications as then amended or supplemented would include any untrue statement of
a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
existing when the Prospectus, the Pricing Disclosure Package, any such Issuer Free Writing Prospectus or any Testing-the-Waters Communications
is delivered to a purchaser, not misleading; (vi) of the receipt by the Company of any notice of objection of the Commission to the use
of the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Securities Act;
and (vii) of the receipt by the Company of any notice with
respect to any suspension of the qualification of the Shares for offer and sale in any jurisdiction or the initiation or threatening of
any proceeding for such purpose; and the Company will use its reasonable best efforts to prevent the issuance of any such order suspending
the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure
Package, any Issuer Free Writing Prospectus or the Prospectus or any Testing-the-Waters Communications or suspending any such qualification
of the Shares and, if any such order is issued, will obtain as soon as possible the withdrawal thereof.
(e) Ongoing
Compliance. (1) If during the Prospectus Delivery Period (i) any event or development shall occur or condition shall exist as a result
of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material
fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to
a purchaser, not misleading or (ii) it is necessary to amend or supplement the Prospectus to comply with law, the Company will promptly
notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c) above, file with the Commission and furnish to the
Underwriters and to such dealers as the Underwriters may designate such amendments or supplements to the Prospectus (or any document to
be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so
amended or supplemented (or any document to be filed with the Commission and incorporated by reference therein) will not, in the light
of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with
law and (2) if at any time prior to the Closing Date (i) any event or development shall occur or condition shall exist as a result of
which the Pricing Disclosure Package as then amended or supplemented would include any untrue statement of a material fact or omit to
state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Pricing
Disclosure Package is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Pricing Disclosure
Package to comply with law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph
(c) above, file with the Commission (to the extent required) and furnish to the Underwriters and to such dealers as the Underwriters may
designate, such amendments or supplements to the Pricing Disclosure Package (or any document to be filed with the Commission and incorporated
by reference therein) as may be necessary so that the statements in the Pricing Disclosure Package as so amended or supplemented will
not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be misleading or so that
the Pricing Disclosure Package will comply with law.
(f) Blue
Sky Compliance. To the extent required, the Company will qualify the Shares for offer and sale under the securities or Blue Sky laws
of such jurisdictions as the Underwriters shall reasonably request and will continue such qualifications in effect so long as required
for distribution of the Shares; provided that the Company shall not be required to (i) qualify as a foreign corporation or other
entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii) file any general
consent to service of process in any such jurisdiction or (iii) subject itself to taxation in any such jurisdiction if it is not
otherwise so subject.
(g) Earning
Statement. The Company will make generally available (which may be satisfied by the filing of such statement with the Commission on
its Electronic Data Gathering, Analysis and Retrieval System) to its security holders and the Underwriters as soon as practicable an earning
statement that satisfies the provisions of Section 11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering
a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the “effective date”
(as defined in Rule 158) of the Registration Statement.
(h) Clear
Market. For a period of 90 days after the date of the Prospectus (the “Lock-Up Period”), the Company Parties will not
(i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the
Commission a registration statement under the Securities Act relating to, any shares of Common Stock, TPG Operating Group Units or any
securities convertible into or exercisable or exchangeable for Stock or TPG Operating Group Units or (ii) enter into any swap or other
agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or any such other securities,
or publicly disclose the intention to undertake any of the foregoing, whether any such transaction described in clause (i) or (ii) above
is to be settled by delivery of Common Stock or such other securities, in cash or otherwise, without the prior written consent of J.P.
Morgan Securities LLC other than the Shares to be sold hereunder.
The restrictions described above do not
apply to (i) the issuance of shares of Common Stock, or securities convertible into or exercisable or exchangeable for any shares of Common
Stock, pursuant to the Exchange Agreement, provided that the recipients of such Common Stock or other securities pursuant to this clause
(i) shall deliver a “lock-up” agreement to the Underwriters substantially in the form of Exhibit A hereto with respect to
such Common Stock or other securities (or, if the recipient shall have previously delivered such a “lock-up” agreement, such
Common Stock or other securities will be made subject to the terms of such lock-up); (ii) the issuance of shares of Common Stock or securities
convertible into or exercisable for shares of Common Stock pursuant to the conversion or exchange of convertible or exchangeable securities
or the exercise of warrants or options (including net exercise) or the settlement of restricted stock units (including net settlement),
in each case outstanding on the date of this Agreement and described in the Prospectus; (iii) grants of stock options, stock awards, restricted
stock, restricted stock units, or other equity awards and the issuance of shares of Common Stock or securities convertible into or exercisable
or exchangeable for shares of Stock (whether upon the exercise of stock options or otherwise) to the Company’s employees, officers,
directors, advisors, or consultants pursuant to the terms of an equity compensation plan in effect as of the Closing Date and described
in the Prospectus;
(iv) the filing of any registration statement on Form S-8
or a successor form thereto relating to securities granted or to be granted pursuant to any plan in effect on the date of this Agreement
and described in the Prospectus or any assumed benefit plan pursuant to an acquisition or similar strategic transaction, (iv) the sale
or issuance or entry into an agreement to sell or issue shares of Common Stock or securities convertible into, or exercisable for Common
Stock in connection with the acquisition by the Company or any of its subsidiaries of one or more businesses, products, assets or technologies
(whether by means of merger, stock purchase, asset purchase or otherwise) or in connection with joint ventures, commercial relationships
or other strategic transactions, provided that the aggregate number of shares of Common Stock issued during the Lock-Up Period in such
acquisitions and transactions does not exceed 10% of the fully diluted Common Stock of the Company following the completion of this offering,
provided, further, that the recipients of such shares of Common Stock agree to be bound in writing by an agreement of the same duration
and terms described in this paragraph or (v) the issuance of Class B Common Stock and of TPG Operating Group Units to the extent required
pursuant to the anti-dilution provisions of TPG Operating Group Limited Partnership Agreements.
(i) No
Stabilization. None of the Company Parties nor its subsidiaries or affiliates will take, directly or indirectly, any action designed
to or that could reasonably be expected to cause or result in any unlawful stabilization or manipulation of the price of the Stock.
(j) Reports.
So long as the Shares are outstanding, the Company will furnish to the Underwriters, as soon as they are available, copies of all
reports or other communications (financial or other) furnished to holders of the Shares, and copies of any reports and financial statements
furnished to or filed with the Commission or any national securities exchange or automatic quotation system; provided the Company
will be deemed to have furnished such reports and financial statements to the Underwriters to the extent they are filed on the Commission’s
Electronic Data Gathering, Analysis, and Retrieval system.
(k) Record
Retention. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each Issuer Free Writing
Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act.
6. Further
Agreements of the Selling Stockholders. Each of the Selling Stockholders, severally and not jointly, covenants and agrees with each
Underwriter that:
(a) No
Stabilization. Such Selling Stockholder will not take, directly or indirectly, any action designed to or that would reasonably be
expected to cause or result in any stabilization or manipulation of the price of the Stock.
(b) Tax
Form. It will deliver to the Underwriters prior to or at the Closing Date a properly completed and executed United States Treasury
Department Form W-9 (or other applicable form or statement specified by the Treasury Department regulations in lieu thereof) in order
to facilitate the Underwriters’ documentation of their compliance with the reporting and withholding provisions of the Tax Equity
and Fiscal Responsibility Act of 1982 with respect to the transactions herein contemplated.
(c) Use
of Proceeds. It will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise
make available such proceeds to a subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any activities
of or business with any person that, at the time of such funding or facilitation, is the subject of target of Sanctions, (ii) to fund
or facilitate any activities of or business in any Sanctioned Country or (iii) in any other manner that will result in a violation by
any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.
7. Certain
Agreements of the Underwriters. Each Underwriter hereby represents and agrees that:
(a) It
has not and will not use, authorize use of, refer to or participate in the planning for use of any “free writing prospectus,”
as defined in Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission by the
Company and not incorporated by reference into the Registration Statement and any press release issued by the Company) other than (i)
a free writing prospectus that contains no “issuer information” (as defined in Rule 433(h)(2) under the Securities Act) that
was not included (including through incorporation by reference) in the Preliminary Prospectus or a previously filed Issuer Free Writing
Prospectus, (ii) any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section 3(c) or Section 5(c) above (including
any electronic road show), or (iii) any free writing prospectus prepared by such Underwriter and approved by the Company in advance in
writing (each such free writing prospectus referred to in clauses (i) or (iii), an “Underwriter Free Writing Prospectus”).
(b) It
has not and will not, without the prior written consent of the Company, use any free writing prospectus that contains the final terms
of the Shares unless such terms have previously been included in a free writing prospectus filed with the Commission.
(c) It
is not subject to any pending proceeding under Section 8A of the Securities Act with respect to the offering (and will promptly notify
the Company and the Selling Stockholders if any such proceeding against it is initiated during the Prospectus Delivery Period).
8. Conditions
of Underwriters’ Obligations. The obligation of each Underwriter to purchase the Shares on the Closing Date as provided herein
is subject to the performance by the Company Parties and each of the Selling Stockholders of their respective covenants and other obligations
hereunder and to the following additional conditions:
(a) Registration
Compliance; No Stop Order. No order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding
for such purpose, pursuant to Rule 401(g)(2) or pursuant to Section 8A under the Securities Act, shall be pending before or threatened
by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with the Commission under the Securities
Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance
with Section 5(a) hereof; and all requests by the Commission for additional information shall have been complied with to the reasonable
satisfaction of the Underwriters.
(b) Representations
and Warranties. The respective representations and warranties of the Company Parties and the Selling Stockholders contained herein
shall be true and correct on the date hereof and on and as of the Closing Date; and the statements of each Company Party and its officers
and of each of the Selling Stockholders and their officers made in any certificates delivered pursuant to this Agreement shall be true
and correct on and as of the Closing Date.
(c) No
Downgrade. Subsequent to the earlier of (A) the Applicable Time and (B) the execution and delivery of this Agreement, (i) no downgrading
shall have occurred in the rating accorded to any debt securities, convertible securities or preferred stock issued, or guaranteed by,
the Company or any of its subsidiaries by any “nationally recognized statistical rating organization,” as such term is defined
under Section 3(A)(62) under the Exchange Act and (ii) no such organization shall have publicly announced that it has under surveillance
or review, or has changed its outlook with respect to, its rating of any such debt securities or preferred stock issued or guaranteed
by the Company of any of its subsidiaries (other than an announcement with positive implications of a possible upgrading).
(d) No
Material Adverse Change. No event or condition of a type described in Section 3(h) hereof shall have occurred or shall exist, which
event or condition is not described in each of the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the
Prospectus (excluding any amendment or supplement thereto) and the effect of which in the judgment of the Underwriters makes it impracticable
or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date, on the terms and in the manner contemplated
by this Agreement, the Pricing Disclosure Package and the Prospectus.
(e) Officer’s
Certificate. The Underwriters shall have received on and as of the Closing Date, (x) a certificate of the chief financial officer
or chief accounting officer of the Company and one additional senior executive officer of the Company who is satisfactory to the Underwriters
(i) confirming that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus
and, to the knowledge of such officers, the representations of the Company Parties set forth in Sections 3(b) and 3(d) hereof are true
and correct,
(ii) confirming that the other representations and warranties
of the Company Parties in this Agreement are true and correct and that each Company Party has complied with all agreements and satisfied
all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date, and (iii) to the effect set forth
in paragraphs (a), (c) and (d) above and (y) a certificate of the Selling Stockholders, in form and substance reasonably satisfactory
to the Underwriters, (A) confirming that the representations of such Selling Stockholder set forth in Sections 4(f) and 4(g) hereof is
true and correct and (B) confirming that the other representations and warranties of such Selling Stockholder in this agreement are true
and correct and that the such Selling Stockholder has complied with all agreements and satisfied all conditions on their part to be performed
or satisfied hereunder at or prior to such Closing Date.
(f) Comfort
Letters. (i) On the date of this Agreement and on the Closing Date, Deloitte & Touche LLP shall have furnished to the Underwriters,
at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and
substance reasonably satisfactory to the Underwriters, containing statements and information of the type customarily included in accountants’
“comfort letters” to underwriters with respect to the financial statements and certain financial information contained or
incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided, that
the letter delivered on the Closing Date shall use a “cut-off” date no more than two business days prior to such Closing Date.
(ii) On
the date of this Agreement and on the Closing Date, PricewaterhouseCoopers LLP shall have furnished to the Underwriters, at the request
of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance reasonably
satisfactory to the Underwriters, containing statements and information of the type customarily included in accountants’ “comfort
letters” to underwriters with respect to the financial statements and certain financial information contained or incorporated by
reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided that the letter delivered
on the Closing Date, shall use a “cut-off” date no more than two business days prior to such Closing Date.
(iii) On
the date of this Agreement and on the Closing Date, as the case may be, the Company shall have furnished to the Underwriters a certificate,
dated the respective dates of delivery thereof and addressed to the Underwriters, of its chief financial officer with respect to certain
financial data contained in the Pricing Disclosure Package and the Prospectus, providing “management comfort” with respect
to such information, in form and substance reasonably satisfactory to the Underwriters.
(g) Opinion
and 10b-5 Statement of Counsel for the Company. Weil, Gotshal & Manges LLP, counsel for the Company, shall have furnished to the
Underwriters, at the request of the Company, their written opinion and 10b-5 statement, dated the Closing Date, and addressed to the Underwriters,
in form and substance reasonably satisfactory to the Underwriters.
(h) Opinion
of Tax Counsel for the Company. Davis Polk & Wardwell LLP, tax counsel for the Company, shall have furnished to the Underwriters,
at the request of the Company, their written opinion, dated the Closing Date, and addressed to the Underwriters, in form and substance
reasonably satisfactory to the Underwriters.
(i) [Reserved].
(j) Opinion
and 10b-5 Statement of Counsel for the Underwriters. The Underwriters shall have received on and as of the Closing Date, an opinion
and 10b-5 statement, addressed to the Underwriters, of Ropes & Gray LLP, counsel for the Underwriters, with respect to such matters
as the Underwriters may reasonably request, and such counsel shall have received such documents and information as they may reasonably
request to enable them to pass upon such matters.
(k) No
Legal Impediment to Sale. No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted
or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date, prevent the sale of
the Shares by the Selling Stockholders; and no injunction or order of any federal, state or foreign court shall have been issued that
would, as of the Closing Date, prevent the sale of the Shares by the Selling Stockholders.
(l) Good
Standing. The Underwriters shall have received on and as of the Closing Date, satisfactory evidence of the good standing of each Company
Party and its significant subsidiaries in their respective jurisdictions of organization and their good standing in such other jurisdictions
as the Underwriters may reasonably request, in each case in writing or any standard form of telecommunication from the appropriate governmental
authorities of such jurisdictions.
(m) [Reserved].
(n) Lock-up
Agreements. The “lock-up” agreements, each substantially in the form of Exhibit A hereto, between you and certain shareholders,
officers and directors of the Company, including the Selling Stockholders, relating to sales and certain other dispositions of shares
of Stock or certain other securities, delivered to you on or before the date hereof, shall be in full force and effect on the Closing
Date.
(o) Additional
Documents. On or prior to the Closing Date, the Company Parties and the Selling Stockholders shall have furnished to the Underwriters
such further certificates and documents as the Underwriters may reasonably request.
All opinions, letters, certificates and evidence
mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form
and substance reasonably satisfactory to counsel for the Underwriters.
9. Indemnification
and Contribution.
(a) Indemnification
of the Underwriters by the Company. Each Company Party agrees, jointly and severally, to indemnify and hold harmless each Underwriter,
its affiliates, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act, from and against any and all losses, claims, damages and liabilities (including, without
limitation, reasonably incurred legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim
asserted, as such fees and expenses are incurred), joint or several, that arise out of, or are based upon, (i) any untrue statement or
alleged untrue statement of a material fact contained in the Registration Statement or caused by any omission or alleged omission to state
therein a material fact required to be stated therein or necessary in order to make the statements therein, not misleading, or (ii) any
untrue statement or alleged untrue statement of a material fact contained in the Prospectus (or any amendment or supplement thereto),
any Preliminary Prospectus, any Issuer Free Writing Prospectus, any “issuer information” filed or required to be filed pursuant
to Rule 433(d) under the Securities Act, any Written Testing-the-Waters Communications, any electronic road show or any Pricing Disclosure
Package (including any Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to
state therein a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made,
not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue
statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to
any Underwriter furnished to the Company in writing by such Underwriter expressly for use therein, it being understood and agreed that
the only such information furnished by any Underwriter consists of the information described as such in paragraph (c) below.
(b) Indemnification
of the Underwriters by the Selling Stockholders. Each of the Selling Stockholders, severally and not jointly, in proportion to the
number of Shares to be sold by such Selling Stockholder agrees to indemnify and hold harmless each Underwriter, its affiliates, directors
and officers and each person, if any, who controls such Underwriter within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a) above, in each case except insofar as such losses,
claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission
made in reliance upon and in conformity with any information relating to any Underwriter furnished to the Company in writing by such Underwriter
expressly for use in the Registration Statement, the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus,
any Issuer Free Writing Prospectus, any Written Testing-the-Waters Communications or the Pricing Disclosure Package, it being understood
and agreed that the only such information furnished by any Underwriter consists of the information described as such in paragraph (c)
below, and in each case only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue
statement or omission to state a material fact or alleged untrue statement or omission made in reliance upon and in conformity with the
Selling Stockholders’ Selling Stockholder Information; provided that the liability of any Selling Stockholder pursuant to
this Section 9(b) shall not exceed the total net proceeds (after deducting underwriter discounts and commissions but before deducting
offering expenses) from the sale of the Shares sold by such Selling Stockholder hereunder (the “Selling Stockholder Proceeds”).
(c) Indemnification
of the Company Parties and the Selling Stockholders. Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless
each Company Party, its directors, its officers who signed the Registration Statement and each person, if any, who controls such Company
Party within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act and each of the Selling Stockholders to
the same extent as the indemnity set forth in paragraph (a) above, but only with respect to any losses, claims, damages or liabilities
that arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and
in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter expressly for
use in the Registration Statement, the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free
Writing Prospectus, any Written Testing-the-Waters Communications, any electronic road show or any Pricing Disclosure Package (including
any Pricing Disclosure Package that has subsequently been amended), it being understood and agreed upon that the only such information
furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: the concession
and reallowance figures appearing in the third paragraph under the caption “Underwriting,” and the information contained in
paragraphs thirteen and fourteen under the caption “Underwriting.”
(d) Notice
and Procedures. If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand shall be
brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this
Section 9, such person (the “Indemnified Person”) shall promptly notify the person against whom such indemnification may
be sought (the “Indemnifying Person”) in writing; provided that the failure
to notify the Indemnifying Person shall not relieve it from any liability that it may have under the preceding paragraphs of this Section
9 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure;
and provided, further, that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may
have to an Indemnified Person otherwise than under the preceding paragraphs of this Section 9. If any such proceeding shall be brought
or asserted against an Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person
shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person,
be counsel to the Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this
Section 9 that the Indemnifying Person may designate in such proceeding and shall pay the reasonably incurred fees and expenses of such
proceeding and shall pay the reasonably incurred fees and expenses of such counsel related to such proceeding, as incurred and documented.
In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel
shall be at the expense of such Indemnified Person unless (i) the Indemnifying Person and the Indemnified Person shall have mutually
agreed to the contrary;
(ii) the Indemnifying Person has failed within a reasonable time
to retain counsel reasonably satisfactory to the Indemnified Person; (iii) the Indemnified Person shall have reasonably concluded that
there may be legal defenses available to it that are different from or in addition to those available to the Indemnifying Person; or (iv)
the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person
and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them.
It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same
jurisdiction, be liable for the reasonably incurred fees and expenses of more than one separate firm (in addition to any local counsel)
for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred and documented. Any
such separate firm for any Underwriter, its affiliates, directors and officers and any control persons of such Underwriter shall be designated
in writing by J.P. Morgan Securities LLC and any such separate firm for a Company Party, its directors and officers who signed the Registration
Statement and any control persons of a Company Party shall be designated in writing by the Company and any such separate firm for the
Selling Stockholders shall be designated in writing by an Attorney-in-Fact. The Indemnifying Person shall not be liable for any settlement
of any proceeding effected without its written consent, but if settled with such consent, the Indemnifying Person agrees to indemnify
each Indemnified Person from and against any loss or liability by reason of such settlement. Notwithstanding the foregoing sentence, if
at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for reasonably incurred
fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding
effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by the Indemnifying Person
of such request and (ii) the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior
to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement
of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could
have been sought hereunder by such Indemnified Person, unless such settlement (x) includes an unconditional release of such Indemnified
Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter
of such proceeding and (y) does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf
of any Indemnified Person.
(e) Contribution.
If the indemnification provided for in paragraphs (a), (b) or (c) above is unavailable to an Indemnified Person or insufficient in
respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu
of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result
of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the
Company Parties and the Selling Stockholders, on the one hand, and the Underwriters on the other, from the offering of the Shares or (ii)
if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only
the relative benefits referred to in clause (i) but also the relative fault of the Company Parties and the Selling Stockholders, on the
one hand, and the Underwriters on the other, in connection with the statements or omissions that resulted in such losses, claims, damages
or liabilities, as well as any other relevant equitable considerations.
The relative benefits received by the Company Parties and the Selling
Stockholders, on the one hand, and the Underwriters on the other, shall be deemed to be in the same respective proportions as the net
proceeds (before deducting expenses) received by the Selling Stockholders from the sale of the Shares and the total underwriting discounts
and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus,
bear to the aggregate offering price of the Shares. The relative fault of the Company Parties and the Selling Stockholders, on the one
hand, and the Underwriters on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company
and the Selling Stockholders or by the Underwriters and the parties’ relative intent, knowledge, access to information and opportunity
to correct or prevent such statement or omission.
(f) Limitation
on Liability. The Company Parties, the Selling Stockholders and the Underwriters agree that it would not be just and equitable if
contribution pursuant to paragraph (e) above were determined by pro rata allocation (even if the Selling Stockholders or
the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the
equitable considerations referred to in paragraph (e) above. The amount paid or payable by an Indemnified Person as a result of the losses,
claims, damages and liabilities referred to in paragraph (e) above shall be deemed to include, subject to the limitations set forth above,
any reasonably incurred legal or other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding
the provisions of paragraphs (e) and (f), in no event shall (i) an Underwriter be required to contribute any amount in excess of the
amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Shares
exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue
statement or omission or alleged omission or (ii) a Selling Stockholder be required to contribute any amount in excess of its Selling
Stockholder Proceeds. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall
be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters’ obligations
to contribute pursuant to paragraphs (e) and (f) are several in proportion to their respective purchase obligations hereunder and not
joint.
(g) Non-Exclusive
Remedies. The remedies provided for in this Section 9 paragraphs (a) through (f) are not exclusive and shall not limit any rights
or remedies which may otherwise be available to any Indemnified Person at law or in equity.
10. Effectiveness
of Agreement. This Agreement shall become effective as of the date first written above.
11. Termination.
This Agreement may be terminated in the absolute discretion of the Underwriters, by notice to the Company and the Selling Stockholders,
if after the execution and delivery of this Agreement and on or prior to the Closing Date (i) trading generally shall have been suspended
or materially limited on or by any of the New York Stock Exchange or The Nasdaq Stock Market; (ii) trading of any securities issued or
guaranteed by the Company shall have been suspended on any exchange or in any over-the-counter market; (iii) a general moratorium on commercial
banking activities shall have been declared by federal or New York State authorities; or (iv) there shall have occurred any outbreak or
escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that,
in the judgment of the Underwriters, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale
or delivery of the Shares on the Closing Date on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package
and the Prospectus.
12. Defaulting
Underwriter.
(a) If,
on the Closing Date, any Underwriter defaults on its obligation to purchase the Shares that it has agreed to purchase hereunder on such
date, the non-defaulting Underwriter may in its discretion arrange for the purchase of such Shares by other persons satisfactory to the
Company and the Selling Stockholders on the terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter,
the non-defaulting Underwriter does not arrange for the purchase of such Shares, then the Company and the Selling Stockholders shall be
entitled to a further period of 36 hours within which to procure other persons satisfactory to the non-defaulting Underwriter to purchase
such Shares on such terms. If other persons become obligated or agree to purchase the Shares of a defaulting Underwriter, either the non-defaulting
Underwriter or the Company and the Selling Stockholders may postpone the Closing Date for up to five full business days in order to effect
any changes that in the opinion of counsel for the Company, counsel for the Selling Stockholders or counsel for the Underwriters may be
necessary in the Registration Statement, the Pricing Disclosure Package and the Prospectus or in any other document or arrangement, and
the Company agrees to promptly prepare any amendment or supplement to the Registration Statement, the Pricing Disclosure Package and the
Prospectus that effects any such changes. As used in this Agreement, the term “Underwriter” includes, for all purposes of
this Agreement unless the context otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to this Section 12, purchases
Shares that a defaulting Underwriter agreed but failed to purchase.
(b) If,
after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter by the non-defaulting Underwriter,
the Company and the Selling Stockholders as provided in paragraph (a) above, the aggregate number of Shares that remain unpurchased on
the Closing Date does not exceed one-eleventh of the aggregate number of Shares to be purchased on such date, then the Company and the
Selling Stockholders shall have the right to require each the non-defaulting Underwriter to purchase the number of Shares that such Underwriter
agreed to purchase hereunder on such date plus such Underwriter’s pro rata share (based on the number of Shares that such Underwriter
agreed to purchase on such date) of the Shares of such defaulting Underwriter for which such arrangements have not been made.
(c) If,
after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter by the non-defaulting Underwriter,
the Company and the Selling Stockholders as provided in paragraph (a) above, the aggregate number of Shares that remain unpurchased on
the Closing Date, exceeds one-eleventh of the aggregate amount of Shares to be purchased on such date, or if the Company and the Selling
Stockholders shall not exercise the right described in paragraph (b) above, then this Agreement shall terminate without liability on the
part of the non-defaulting Underwriter. Any termination of this Agreement pursuant to this Section 12 shall be without liability on the
part of the Company, except that the Company Parties and the Selling Stockholders will continue to be liable for the payment of expenses
as set forth in Section 13 hereof and except that the provisions of Section 9 hereof shall not terminate and shall remain in effect.
(d) Nothing
contained herein shall relieve a defaulting Underwriter of any liability it may have to any Company Party, the Selling Stockholders or
any non-defaulting Underwriter for damages caused by its default.
13. Payment
of Expenses.
(a) Whether
or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company Parties, jointly and
severally, will pay or cause to be paid all costs and expenses incident to the performance of their obligations hereunder, including without
limitation, (i) the costs incident to the authorization, issuance, sale, preparation and delivery
of the Shares and any taxes payable in that connection; (ii) the costs incident to the preparation, printing and filing under
the Securities Act of the Registration Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing Disclosure
Package and the Prospectus (including all exhibits, amendments and supplements thereto) and the
distribution thereof; (iii) the fees and expenses of the Company Parties’ counsel, the Selling Stockholders’ counsel and independent
accountants; (iv) the fees and expenses incurred in connection with the registration or qualification and determination of eligibility
for investment of the Shares under the laws of such jurisdictions as the Underwriters may reasonably designate and
the preparation, printing and distribution of a Blue Sky Memorandum (including the related fees and expenses of counsel for the
Underwriters); (v) the cost of preparing stock certificates; (vi) the costs and charges
of any transfer agent and any registrar; (vii) all expenses and application fees incurred in connection with any filing with, and clearance
of the offering by, FINRA (including the related reasonably incurred fees and expenses of counsel for the Underwriters not to exceed
$25,000); (viii) all expenses incurred by the Company Parties in connection with any “road show” presentation to potential
investors; and (ix) all expenses and application fees related to the listing of the Shares
on the Exchange.
(b) If
(i) this Agreement is terminated pursuant to Section 11(ii), (ii) the Selling Stockholders for any
reason fail to tender the Shares for delivery to the Underwriters or (iii) the Underwriters decline to purchase the Shares for any reason
permitted under this Agreement, the Company Parties agree, jointly and severally, to reimburse the Underwriters for all out-of-pocket
costs and expenses (including the fees and expenses of their counsel) reasonably incurred by the Underwriters in connection with this
Agreement and the offering contemplated hereby; provided that, in the case of a termination pursuant to Section 12, the Company Parties
and the Selling Stockholders shall have no obligation to reimburse a defaulting Underwriter for such costs and expenses.
14. Persons
Entitled to Benefit of Agreement. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective
successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred
to in Section 9 hereof. Nothing in this Agreement is intended or shall be construed to give any other person any legal or equitable right,
remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Shares from any Underwriter shall
be deemed to be a successor merely by reason of such purchase.
15. Survival.
The respective indemnities, rights of contribution, representations, warranties and agreements of the Company Parties, the Selling Stockholders
and the Underwriters contained in this Agreement or made by or on behalf of the Company Parties, the Selling Stockholders or the Underwriters
pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of and payment for the Shares and shall
remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company
Parties, the Selling Stockholders or the Underwriters or the directors, officers, controlling persons or affiliates referred to in Section
9 hereof.
16. Certain
Defined Terms. For purposes of this Agreement, (a) except where otherwise expressly provided, the term “affiliate” has
the meaning set forth in Rule 405 under the Securities Act; (b) the term “business day” means any day other than a day on
which banks are permitted or required to be closed in New York City; and (c) the term “subsidiary” has the meaning set forth
in Rule 405 under the Securities Act, provided that such term shall not include any portfolio company or other investment held by any
fund or other investment vehicle sponsored or managed by the Company or any of its affiliates.
17. Compliance
with USA Patriot Act. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October
26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including
the Company Parties and the Selling Stockholders, which information may include the name and address of their respective clients, as well
as other information that will allow the Underwriters to properly identify their respective clients.
18. Miscellaneous.
(a) Notices. All notices
and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted and confirmed
by any standard form of telecommunication. Notices to the Underwriters shall be given to J.P. Morgan Securities LLC, 383 Madison Avenue,
New York, New York 10179 (fax: (212) 622-8358); Attention: Equity Syndicate Desk. Notices to the Company Parties shall be given to it
at TPG Inc., 301 Commerce Street, Suite 3300, Fort Worth, Texas 76102, Telephone: (817) 871-4000, Attention: General Counsel. Notices
to the Selling Stockholders shall be given to the Attorneys-in-Fact at 301 Commerce Street, Suite 3300, Fort Worth, Texas 76102, Telephone:
(817) 871-4000, Attention: General Counsel.
(b) Governing
Law. This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by and construed
in accordance with the laws of the State of New York.
(c) Submission
to Jurisdiction. Each Company Party and the Selling Stockholders hereby submits to the exclusive jurisdiction of the U.S. federal
and New York state courts in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to
this Agreement or the transactions contemplated hereby. Each Company Party and the Selling Stockholders waive any objection which it may
now or hereafter have to the laying of venue of any such suit or proceeding in such courts. Each Company Party and the Selling Stockholders
agree that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding upon such Company
Party or Selling Stockholder and may be enforced in any court to the jurisdiction of which such Company Party or Selling Stockholder is
subject by a suit upon such judgment.
(d) [Reserved].
(e) [Reserved].
(f) Waiver
of Jury Trial. Each of the parties hereto hereby waives any right to trial by jury in any suit or proceeding arising out of or relating
to this Agreement.
(g) Recognition
of the U.S. Special Resolution Regimes.
(i) In the event that any Underwriter
that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of
this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would
be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws
of the United States or a state of the United States.
(ii) In the event that any Underwriter
that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime,
Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent
than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the
United States or a state of the United States.
As used in this Section 18(g):
“BHC Act Affiliate” has the
meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k).
“Covered Entity” means any of
the following:
(i) a “covered entity” as
that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);
(ii) a “covered bank” as that term is defined
in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or
(iii) a “covered FSI” as that term is defined
in, and interpreted in accordance with, 12 C.F.R. § 382.2(b).
“Default Right” has the meaning assigned to that
term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable.
“U.S. Special Resolution Regime”
means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall
Street Reform and Consumer Protection Act and the regulations promulgated thereunder.
(h) Counterparts.
This Agreement may be executed by any one or more of the parties hereto in any number of counterparts, each of which shall be deemed
to be an original, but all such counterparts shall together constitute one and the same instrument. Counterparts may be delivered via
facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions
Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
(i) Amendments
or Waivers. No amendment or waiver of any provision of this Agreement, nor any consent or approval
to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto.
(j) Headings.
The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning or
interpretation of, this Agreement.
If the foregoing is in accordance with your
understanding, please indicate your acceptance of this Agreement by signing in the space provided below.
|
Very truly yours, |
|
|
|
|
|
|
TPG Inc. |
|
|
|
|
|
|
|
|
|
By: |
/s/ Jack Weingart |
|
|
|
Name: Jack Weingart |
|
|
|
Title: Chief Financial Officer |
|
|
TPG Opco Holdings, L.P.
By: TPG LpCo-1, Inc., its General Partner |
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Martin Davidson |
|
|
|
Name: Martin Davidson |
|
|
|
Title: Chief Accounting Officer
of the General Partner |
|
|
TPG Operating Group II, L.P.
By: TPG Holdings II-A, LLC, its General Partner |
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Martin Davidson |
|
|
|
Name: Martin Davidson |
|
|
|
Title: Chief Accounting Officer
of the General Partner |
|
|
|
|
|
|
By: |
/s/ Jack Weingart |
|
|
|
Name: Jack Weingart |
|
|
|
Title: Attorney-in-Fact |
|
|
|
|
|
|
|
|
|
|
|
|
|
As Attorney-in-Fact acting on behalf of each of the Selling Stockholders named in Schedule 2 to this Agreement. |
|
Accepted: As of the date first written above
J.P. Morgan Securities LLC
By /s/ Alaoui Zenere
Name: Alaoui Zenere
Title: Managing Director
Morgan Stanley & Co. LLC
By /s/ Jack Lysohir
Name: Jack Lysohir
Title: Executive Director
Schedule 1
Underwriter |
Number of Shares |
J.P. Morgan Securities LLC |
13,197,878 |
Morgan Stanley & Co. LLC |
2,329,037 |
Total |
15,526,915 |
Schedule 2
Selling Stockholder: |
Number of
Underwritten Shares: |
|
|
1. David Bonderman |
1,533,898 |
2. James G. Coulter |
1,283,898 |
3. Jon Winkelried |
1,000,000 |
4. Jack Weingart |
308,468 |
5. Todd Sisitsky |
712,958 |
6. Anilu Vazquez-Ubarri |
101,937 |
7. Maya Chorengel |
74,773 |
8. Jonathan Coslet |
1,000,000 |
9. Kelvin Davis |
822,017 |
10. Nehal Raj |
250,858 |
11. Jeffrey Rhodes |
408,675 |
12. Ganendran Sarvananthan |
172,705 |
13. David Trujillo |
397,510 |
14. Bradford Berenson |
90,895 |
15. Martin Davidson |
39,317 |
16. Joann Harris |
25,484 |
17. TPG GP A, LLC |
16,949 |
18. TPG Group Holdings (SBS), L.P. |
33,899 |
19. New TPG GP Advisors, Inc. |
16,949 |
20. Roseworth Investments Limited |
687,961 |
21. Zelcova Barn 314 LLC |
550,767 |
22. Red Maple Barn 159 Irrevocable Trust |
199,233 |
23. [Partner Group 1] |
770,000 |
24. [Partner Group 2] |
309,745 |
25. [Partner Group 3] |
330,145 |
26. [Partner Group 4] |
224,117 |
27. [Partner Group 5] |
369,112 |
28. [Partner Group 6] |
455,094 |
29. [Partner Group 7] |
479,589 |
30. [Partner Group 8] |
614,524 |
31. [Partner Group 9] |
796,755 |
32. [Partner Group 10] |
655,208 |
33. [Partner Group 11] |
535,145 |
34. [Partner Group 12] |
258,330 |
Total: |
15,526,915 |
Annex A
| a. | Pricing Disclosure Package |
None.
| b. | Pricing Information Provided Orally by Underwriters |
Public Offering Price per Share: Variable
Exhibit A
FORM OF LOCK-UP AGREEMENT
[Attached]
FORM OF LOCK-UP AGREEMENT
February 26, 2024
J.P. MORGAN SECURITIES LLC
383 Madison Avenue
New York, New York 10179
MORGAN STANLEY & CO. LLC
1585 Broadway
New York, New York, 10036
Re: TPG
Inc. --- Public Offering
Ladies and Gentlemen:
The undersigned understands
that you, the Underwriters, propose to enter into an underwriting agreement (the “Underwriting Agreement”) with TPG
Inc., a Delaware corporation (the “Company”), and the Selling Stockholders listed in Schedule 2 to the Underwriting
Agreement, providing for the public offering (the “Public Offering”) by the Underwriters, of Class A common stock,
$0.001 par value per share, of the Company (the “Class A Common Stock”). The Company’s Class A Common Stock,
non-voting Class A common stock, $0.001 par value per share and Class B common stock, $0.001 par value per share are collectively referred
to herein as the “Common Stock.” Capitalized terms used herein and not otherwise defined shall have the meanings set
forth in the Underwriting Agreement.
“Affiliate”
shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by or is under common control
with, such Person; provided, that (i) no investment fund, managed account or similar contractual agreement managed by TPG Operating Group
II, L.P., a Delaware limited partnership (the “TPG OG Partnership”) or any subsidiary of the TPG OG Partnership or
portfolio company of it shall be considered an Affiliate of the Company or the TPG OG Partnership for purposes of this Agreement, and
(ii) none of the undersigned shall be deemed, solely as a result of its direct or indirect investment in the Company or the TPG OG Partnership,
to be an Affiliate of the Company, the TPG OG Partnership or any subsidiary of the TPG OG Partnership for purposes of this Agreement.
“Affiliated” shall have a correlative meaning.
In consideration of the agreement
by the Underwriters to purchase and make the Public Offering of the Shares (as defined in the Underwriting Agreement), and for other good
and valuable consideration receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent
of J.P. Morgan Securities LLC, the undersigned will not, and will not cause any direct or indirect Affiliate that it controls to, during
the period beginning on the date of this letter agreement (this “Letter Agreement”) and ending at the close of business
90 days after the date of the final prospectus relating to the Public Offering (the “Prospectus”) (such period,
the “Restricted Period”),
(1) offer, pledge,
sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant
to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock, any TPG Operating Group Units,
or any securities convertible into or exercisable or exchangeable for Common Stock or TPG Operating Group
Units (including, without limitation, Common Stock, TPG Operating Group Units, or such other securities which may be deemed to be beneficially
owned by the undersigned in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”)
and securities which may be issued upon exercise of a stock option or warrant) (collectively with the Common Stock, “Lock-Up
Securities”), (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of
the economic consequences of ownership of the Lock-Up Securities, whether any such transaction described in clause (1) or (2) above is
to be settled by delivery of Lock-Up Securities, in cash or otherwise, (3) make any demand for or exercise any right with respect to the
registration of any Lock-Up Securities, or (4) publicly disclose the intention to do any of the foregoing. The undersigned acknowledges
and agrees that the foregoing precludes the undersigned from engaging in any hedging or other transactions or arrangements (including,
without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward,
swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably
be expected to lead to or result in, a sale or disposition or transfer (whether by the undersigned or any other person) of any economic
consequences of ownership, in whole or in part, directly or indirectly, of any Lock-Up Securities, whether any such transaction or arrangement
(or instrument provided for thereunder) would be settled by delivery of Lock-Up Securities, in cash or otherwise.
Notwithstanding the foregoing,
the undersigned may:
(a) transfer the undersigned’s
Lock-Up Securities:
(i) as a bona fide
gift or gifts, or for bona fide estate planning purposes,
(ii) by will or intestacy,
(iii) to any immediate
family member, or to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, or if
the undersigned is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust (for purposes of
this Letter Agreement, “immediate family” shall mean any relationship by blood, current or former marriage, domestic
partnership or adoption, not more remote than first cousin), or from such trust to the undersigned,
(iv) to a partnership,
limited liability company or other entity of which the undersigned and the immediate family of the undersigned are the legal and beneficial
owner of all of the outstanding equity securities or similar interests,
(v) to a nominee
or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i) through (iv) above,
(vi) if the undersigned
is a corporation, partnership, limited liability company, trust or other business entity, (A) to another corporation, partnership, limited
liability company, trust or other business entity that is an Affiliate (as defined in Rule 405 promulgated under the Securities Act of
1933, as amended) of the undersigned, or to any investment fund or other entity controlling, controlled by, managing or managed by or
under common control with the undersigned or Affiliates of the undersigned (including, for the avoidance of doubt, where the undersigned
is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B) as
part of a distribution to members, limited partners, Affiliates or shareholders of the undersigned,
(vii) by operation
of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement,
(viii) pursuant to
an order of a court or regulatory agency having jurisdiction over the undersigned,
(ix) to the Company
or its Affiliates from an employee or service provider of the Company upon death, disability or termination of employment, in each case,
of such employee or service provider,
(x) as part of a
sale of the undersigned’s Lock-Up Securities acquired in open market transactions on or after the closing date for the Public Offering,
(xi) to the Company
or its Affiliates in connection with the vesting, settlement, or exercise of restricted stock units, restricted stock, performance restricted
stock units, performance restricted stock, phantom stock, options, warrants or other rights to purchase shares of Common Stock (including,
in each case, by way of “net” or “cashless” exercise), including for the payment of exercise price and tax and
remittance payments due as a result of the vesting, settlement, or exercise of such restricted stock units, restricted stock, performance
restricted stock units, performance restricted stock, phantom stock, options, warrants or rights, provided that any such shares of Common
Stock received upon such exercise, vesting or settlement shall be subject to the terms of this Letter Agreement, and provided further
that any such restricted stock units, restricted stock, performance restricted stock units, performance restricted stock, phantom stock,
options, warrants or rights are held by the undersigned pursuant to an agreement or equity awards granted under a stock incentive plan
or other equity award plan, each such agreement or plan which is described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus, including the documents incorporated by reference thereto,
(xii) pursuant to
a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by the Board of Directors of
the Company and made to all holders of the Company’s capital stock involving a Change of Control (as defined below) of the Company
(for purposes hereof, “Change of Control” shall mean the transfer (whether by tender offer, merger, consolidation or
other similar transaction), in one transaction or a series of related transactions, to a person or group of Affiliated persons, of shares
of capital stock if, after such transfer, such person or group of Affiliated persons would hold at least a majority of the outstanding
voting securities of the Company (or the surviving entity)); provided that in the event that such tender offer, merger, consolidation
or other similar transaction is not completed, the undersigned’s Lock-Up Securities shall remain subject to the provisions of this
Letter Agreement, or
(xiii) to the Company
or any of its Affiliates as permitted under the Exchange Agreement, including in connection with exchanges qualifying under Section 351
of the Internal Revenue Code of 1986, as amended, provided, that any such shares of Common Stock received upon such exchange shall remain
subject to the provisions of this Letter Agreement and provided further that, to the extent a public announcement or filing under the
Exchange Act, if any, is required of or voluntarily made by or on behalf of the undersigned or the Company regarding the transfer, conversion,
reclassification, redemption or exchange, as applicable, such announcement or filing shall include a statement explaining the circumstances
of such transfer, or that such transfer, conversion, reclassification, redemption or exchange, occurred pursuant to the terms of the Exchange
Agreement, as applicable, and no transfer of the shares of Common Stock or other securities received upon exchange may be made during
the Restricted Period other than as may be permitted by this Letter Agreement;
provided that (A) in the case of any
transfer or distribution pursuant to clause (a)(i), (ii), (iii), (iv), (v), (vi) and (vii), such transfer shall not involve a disposition
for value and each donee, devisee, transferee or distributee shall execute and deliver to the Representatives a lock-up letter in the
form of this Letter Agreement and (B) in the case of any transfer or distribution pursuant to clause (a) (i), (ii), (iii), (iv), (v),
(vi) and (x), no filing by any party (donor, donee, devisee, transferor, transferee, distributer or distributee) under the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or other public announcement shall be required or shall be made
voluntarily during the Restricted Period in connection with such transfer or distribution (other than a filing on a Form 4 or Form 5 made
after the expiration of the Restricted Period referred to above);
(b) exercise options, settle
restricted stock units, restricted stock, performance restricted stock units, performance restricted stock, phantom stock, or other equity
awards or exercise warrants outstanding as of the date granted pursuant to plans described in the Registration Statement, the Pricing
Disclosure Package, and the Prospectus, including the documents incorporated by reference thereto; provided that any Lock-Up Securities
received upon such exercise, vesting or settlement shall be subject to the terms of this Letter Agreement, including the terms of section
(a)(xi) of this Letter Agreement;
(c) convert outstanding
preferred stock, warrants to acquire preferred stock or convertible securities into shares of Common Stock or TPG Operating Group Units
or warrants to acquire shares of Common Stock or TPG Operating Group Units; provided that any such shares of Common Stock or warrants
received upon such conversion shall be subject to the terms of this Letter Agreement;
(d) establish trading plans
pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Lock-Up Securities; provided that (1) such plans do
not provide for the transfer of Lock-Up Securities during the Restricted Period and (2) to the extent a public announcement or filing
under the Exchange Act, if any, is required or voluntarily made by or on behalf of the undersigned or the Company regarding the establishment
of such plan, such announcement or filing shall include a statement to the effect that no transfer of Lock up Securities may be made under
such plan during the Restricted Period;
(e) transfer shares of
Class A Common Stock in a transaction effectuated pursuant to a trading plan under Rule 10b5-1 that has been entered into by the undersigned
prior to the date of this Letter Agreement; provided that (i) such trading plan under Rule 10b5-1 will not be amended or otherwise modified
to increase shares scheduled for sale thereunder during the Restricted Period and (ii) any public announcement or filings under the Exchange
Act made in connection with this clause (e) shall include an explanatory footnote stating the nature of the transfer; and
(f) sell the Undersigned’s
Lock-Up Securities pursuant to the Underwriting Agreement.
In furtherance of the foregoing,
the Company, and any duly appointed transfer agent for the registration or transfer of the securities described herein, are hereby authorized
to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement.
The undersigned hereby
consents to receipt of this Letter Agreement in electronic form and understands and agrees that this Letter Agreement may be signed electronically.
In the event that any signature is delivered by facsimile transmission, electronic mail (including pdf or any electronic signature complying
with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or signature complying with the U.S. federal ESIGN Act of 2000, e.g.,
www.docusign.com or www.echosign.com) or otherwise by electronic transmission evidencing an intent to sign this Letter Agreement, such
facsimile transmission, electronic mail or other electronic transmission shall create a valid and binding obligation of the undersigned
with the same force and effect as if such signature were an original. Execution and delivery of this Letter Agreement by facsimile transmission,
electronic mail or other electronic transmission is legal, valid and binding for all purposes.
The undersigned hereby
represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement. All authority herein conferred
or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives
of the undersigned.
Nothing in this Letter
Agreement shall prevent the undersigned from making a demand for, or exercising any right with respect to, the registration of the undersigned’s
Common Stock, provided that (i) no sales of Common Stock shall be made in connection with any such demand or any such exercise by the
undersigned or any of its Affiliates prior to the expiration of the Restricted Period and (ii) no filing by any party (donor, donee, devisee,
transferor, transferee, distributer or distributee) under the Exchange Act, or other public announcement shall be required or shall be
made voluntarily in connection with any such demand or any such exercise prior to the expiration of the Restricted Period; provided further
that in no event shall the Company be permitted to take an action in violation of Section 5(h) of the Underwriting Agreement.
If, prior to the expiration
of the Restricted Period, J.P. Morgan Securities LLC consents to release or waive any prohibition set forth in this Lock-Up Agreement
on the transfer of shares of Lock-Up Securities held by any director, officer or shareholder of 5% or more of the Common Stock of the
Company (a “Triggering Release”), then a number of the undersigned’s Lock-Up Securities subject to this agreement
shall also be released from the restrictions set forth herein on a pro rata basis,
such number of securities being the total number
of securities held by the undersigned on the date of the Triggering Release with respect to the Company or TPG Operating Group, as applicable,
that are subject to this agreement multiplied by a fraction, the numerator of which shall be the number of securities of the Company or
TPG Operating Group Units, as applicable, released pursuant to the Triggering Release and the denominator of which shall be the total
number of securities of the Company or TPG Operating Group, as applicable, held by the Triggering Release Party on such date. Notwithstanding
the foregoing, the provisions of this paragraph will not apply (1) if the release or waiver is effected solely to permit a transfer not
involving a disposition for value and the transferee agrees in writing to be bound by the same terms described in this Lock-Up Agreement
to the extent and for the duration that such terms remain in effect at the time of transfer, (2) in the case of any secondary underwritten
public offering of Common Stock, (3) if the release or waiver is granted to any individual party by J.P. Morgan Securities LLC in an amount,
individually or in the aggregate, less than or equal to 1% of the Company’s total fully-diluted shares of Class A Common Stock (calculated
as of the closing date of the Public Offering) or (4) if the release or waiver is granted due to circumstances of an emergency or hardship
as determined by J.P. Morgan Securities LLC in its sole judgment. The undersigned further acknowledges that J.P. Morgan Securities LLC
is under no obligation to inquire into whether, or to ensure that, the Company notifies the undersigned of the consent by J.P. Morgan
Securities LLC of any such release or waiver, which is a matter between the undersigned and the Company.
The undersigned acknowledges
and agrees that the Underwriters have not provided any recommendation or investment advice nor have the Underwriters solicited any action
from the undersigned with respect to the Public Offering of the Shares and the undersigned has consulted their own legal, accounting,
financial, regulatory and tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although
the Underwriters may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with
the Public Offering, the Underwriters are not making a recommendation to you to enter into this Letter Agreement, participate in the Public
Offering, or sell any Shares at the price determined in the Public Offering, and nothing set forth in such disclosures is intended to
suggest that the Underwriters are making such a recommendation.
The undersigned understands
that, if (1) prior to the execution of the Underwriting Agreement, the Company, on behalf of the Selling Stockholders, or the Underwriters
advise the other party in writing that they have determined not to proceed with the Public Offering, (2) prior to the execution of the
Underwriting Agreement, the Registration Statement filed with the Commission with respect to the Public Offering is withdrawn or (3) the
Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment
for and delivery of the Common Stock to be sold thereunder, pursuant to its terms, the undersigned shall be released from all obligations
under this Letter Agreement. The undersigned understands that the Underwriters are entering into the Underwriting Agreement and proceeding
with the Public Offering in reliance upon this Letter Agreement.
This Letter Agreement and
any claim, controversy or dispute arising under or related to this Letter Agreement shall be governed by and construed in accordance with
the laws of the State of New York.
|
Very truly yours, |
|
|
|
|
[NAME OF Holder/Officer/ Director] |
|
|
|
|
By: |
|
|
|
Name: |
|
|
Title: |
Grafico Azioni TPG (NASDAQ:TPG)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni TPG (NASDAQ:TPG)
Storico
Da Feb 2024 a Feb 2025